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ABSTRACT
The effects of two selective fi- opioid agonists DAMGO and DALDA, and a selective k- opioid 
agonist U50,488H on blood pressure and heart rate have been compared in the chronically 
instrumented and awake sheèp. Differences in the heart rate response to p- and K-opioid agonists 
in vivo w^edemonstrated. The mechanism behind the heart rate response to all three opioid agonists 
was investigated by studying the effects of p- and K-agonists on baroreflex sensitivity and the 
involvement of sympathetic activity in the heart rate response to K-opioid agonists. The site and 
mechanism of action involved in the effects of DAMGO and DALDA on the baroreflex were further 
investigated in vivo. The opioid receptor agonists involved in these studies are undergoing 
development as obstetrical analgesics for clinical use hence the influence of pregnancy on the effects 
of p- and K-opioid agonists on blood pressure, heart rate and baroreflex sensitivity were investigated.
The mechanism responsible for the blood pressure effects of p-opioid agonists observed in vivo was 
investigated in vitro using the isolated and perfused guinea pig heart. The effects of DAMGO and 
DALDA on inotropy, chronotropy and coronary flow has been demonstrated in the spontaneously 
beating heart. Differences in the inotropic response to DAMGO and DALDA in the absence of their 
chronotropic influence was demonstrated in electrically paced hearts. Inotropic responses to 
DAMGO and DALDA have been shown to be influenced by the contractile condition of the heart.
The potential therapeutic efficacy of p-opioid agonists has been investigated by studying the 
development of tolerance to their cardiovascular effects in vivo and in vitro. DAMGO and DALDA
have been shown to induce rapid tolerance to blood pressure responses and inotropic responses in 
vivo and in vitro respectively. Differences in the relative potencies of DAMGO and DALDA was 
confirmed in all studies.
SUMMARY
1 .  T h e  h i s t o r y  o f  t h e  o p i o i d  r e c e p t o r  s y s t e m  i s  r e v i e w e d .  T h e  c l a s s i f i c a t i o n  a n d  d i s t r i b u t i o n  o f
o p i o i d  r e c e p t o r s ,  r e c e p t o r  s u b t y p e s ,  t h e i r  e n d o g e n o u s  l i g a n d s  a n d  t h e  d e v e l o p m e n t  o f  h i g h l y
s e l e c t i v e  a g o n i s t s  a n d  a n t a g o n i s t s  i s  d i s c u s s e d  w i t h  r e f e r e n c e  t o  t h e  c l o n i n g  o f  o p i o i d  r e c e p t o r s  a n d
t h e n  t r a n s d u c t i o n  m e c h a n i s m s .  A  d i s c u s s i o n  o f  t h e  r e g u l a t i o n  o f  t h e  c a r d i o v a s c u l a r  s y s t e m  i n c l u d i n g
t h a t  o f  b l o o d  p r e s s u r e ,  h e a r t  r a t e  a n d  t h e  b a r o r e f l e x  i s  p r e s e n t e d  w i t h  c o n s i d e r a t i o n  o f  t h e  i n f l u e n c e
o f  p r e g n a n c y  o n  t h e  s y s t e m .  T h e  l i t e r a t u r e  o n  t h e  e f f e c t s  o f  o p i o i d s  o n  c a r d i o v a s c u l a r  r e g u l a t i o n  i s  
r e v i e w e d .
2 .  I n  o r d e r  t o  a s s e s s  t h e  c a r d i o v a s c u l a r  e f f e c t s  o f  s y s t e m i c a l l y  a d m i n i s t e r e d  o p i o i d  p e p t i d e s ,  c h a n g e s  
m  b l o o d  p r e s s u r e  a n d  h e a r t  r a t e  w e r e  o b s e r v e d  a f t e r  i n t r a v e n o u s  a d m i n i s t r a t i o n  o f  U 5 0 . 4 8 8 H
3 , 4 . d i c h l o r o - N - [ 2 - ( l . p r r r o l i d i n y l ) c y c l o h e x y l ] b e n z e n e a c e t a m i d e ) ,  a  s e l e c t i v e  K - o p i o i d  r e c e p t o r
a g o m s t ,  a n d  t w o  s e l e c t i v e  p - o p i o i d  r e c e p t o r  a g o n i s t s ,  D A L D A  ( T y r - D - A r g - P h e - L y s )  a n d  D A M G O  
( D - A l a 2,7 V - M e - P h e 4, G l y 5- o l ] e n k e p h a i i n  i n  n o n p r e g n a n t  a n d  p r e g n a n t  s h e e p .  I n t r a v e n o u s  
a d m i n i s t r a t i o n  o f  a l l  t h r e e  a g o n i s t s  ( U 5 0 , 4 8 8 H  ( 1 . 2  m g / k g ) ,  D A L D A  ( 0 . 3 m g / k g )  a n d  D A M G O  ( 0 .3  
m g / k g ) )  t o  t h e  a w a k e  s h e e p  r e s u l t e d  i n  a n  i m m e d i a t e  i n c r e a s e  i n  b l o o d  p r e s s u r e .  T h e  p r e s s o r  
r e s p o n s e  t o  U 5 0 , 4 8 8 H  w a s  a c c o m p a n i e d  b y  a n  i n c r e a s e  i n  h e a r t  r a t e  a n d  b o t h  e f f e c t s  w e r e  n a l o x o n e -  
s e n s i t iv e .  I n  c o n t r a s t ,  t h e r e  w a s  n o  a c c o m p a n y i n g  c h a n g e  i n  h e a r t  r a t e  t o  D A L D A  o r  D A M G O .  T h e  
p r e s s o r  r e s p o n s e  t o  D A M G O  a n d  D A L D A  w a s  s i g n i f i c a n t l y  a t t e n u a t e d  i n  p r e g n a n t  a n i m a l s .  I n  
c o n t r a s t ,  t h e r e  w a s  n o  d i f f e r e n c e  b e t w e e n  t h e  p r e s s o r  r e s p o n s e  t o  U 5 0 4 8 8 H  i n  n o n p r e g n a n t  a n d
pregnant sheep, but the tachycardia was more pronounced in pregnant animals. It was hypothesized 
that the lack of a reflex bradycardia to the pressor responses of both the p- and K-opioid receptor 
agonists was due to a blunting of baroreflex-mediated bradycardia. The reflex bradycardia to 
norepinephrine (0.6 pg/kg/min) was significantly reduced in the presence of DAMGO but not 
U50,488H. In view of the lack of effect of U50,488H on the baroreflex, it was further hypothesized 
that the tachycardia it elicited was due to an increase in sympathetic activity. Pretreatment with 
propranolol (0.1 mg/kg) completely blocked the tachycardia elicited by U50,488H. These data 
suggest that the lack of a reflex bradycardia to the pressor response of p-receptor agonists is due to 
a blunting of baroreflex-mediated bradycardia. In contrast, the increase in heart rate caused by 
U50,488H is mediated by sympathetic activation of the heart.
3. In order to assess the site and mechanism by which p-agonists cause an attenuation of baroreflex 
sensitivity, further investigations were carried out using the highly polar p-agonist DALDA, which 
has been shown to have a limited ability to cross the blood brain barrier. Furthermore, as the long 
term goal of the laboratory has been to develop these peptides for clinical obstetrical use, the effects 
of these peptides on baroreflex sensitivity in pregnancy was also investigated. The reflex bradycardia 
to norepinephrine (0.4 - 0.6pg / min) was significantly blunted in the presence of both DAMGO and 
DALDA in pregnant and nonpregnant animals. In view of the limited ability of DALDA to get 
across the blood brain barrier, it was hypothesized that the blunting of baroreflex-mediated
bradycardia by p-agonists occurs at a peripheral site. Pretreatment with the quaternary opioid 
antagonist, naloxone methiodide (0.4 - 0.6 pg/kg/h) completely blocked the attenuation of baroreflex 
sensitivity by DAMGO and DALDA in both nonpregnant and pregnant animals. In order to 
investigate the baroreceptors as a possible site of action as well as address the possibility of these 
drugs exacerbating hemorrhage-induced hypotension in labor and delivery, the effect of both p- 
agonists on baroreflex-mediated tachycardia to a hypotensive stimulus was investigated. The reflex 
tachycardia to sodium nitroprusside (10 pg/kg/min) remained unchanged in the presence of DAMGO 
or DALDA in both nonpregnant and pregnant animals. These data suggests that the blunting of 
baroreflex-mediated bradycardia by DAMGO and DALDA has a peripheral site and mechanism. 
Furthermore, the lack of any effect on baroreflex-mediated tachycardia indicates these p-agonists are 
not acting at the level of the baroreceptors.
(]3cvwe  ^ CiQ.pp'y
4. Further studies carried out by a collaborator^showed 44-agonists while increasing blood pressure 
in the sheep had no effect on peripheral resistance. However, there was a concommitant increase in 
cardiac output. These studies indicated the pressor responses of DAMGO and DALDA was most 
likely due to an increase in the contractility of the heart. The mechanism behind the pressor responses 
previously reported for DAMGO and DALDA was therefore investigated in vitro using the isolated 
and perfused guinea pig heart. The investigation was founded on the hypothesis that the increase in 
blood pressure observed with DAMGO and DALDA in vivo is as a result of a direct effect of these 
p-agonists to increase the contractility of the heart. The expectations were therefore that these
agonists would produce a positive inotropic effect on the isolated heart. Pilot studies with the 
isolated guinea pig heart however revealed conflicting results regarding the inotropic effects of 
DAMGO and DALDA. It was further hypothesized that the pre-existing condition of the heart may 
determine the inotropic effect of p-agonists on the heart. Hence the effects of DAMGO and 
DALDA on the isolated and perfused guinea pig heart was further investigated under four different 
conditions, two of which were "stress" paradigms: (1) Spontaneous heart rate (2) During electrical 
pacing of the heart to eliminate the chronotropic effects of DAMGO and DALDA (3) Low flow 
ischemia induced by rapid electrical pacing (4) and following 30-mins of no flow ischemia . DALDA 
(10'"- 10'9M) caused a dose dependent decrease in the force of contraction, heart rate and coronary 
flow in spontaneously beating hearts. There was a decrease in the force of contraction, coronary 
flow and heart rate at 10'nM DAMGO while subsequent doses (10*9- 10*7M) resulted in increases 
of all three parameters. Elimination of chronotropic effects with electrical pacing at spontaneous rate 
unmasked dose-dependent negative inotropic effects for both DAMGO and DALDA (10"" - 1 0 ‘7M) 
that were bigger in magnitude than those observed in the spontaneously beating hearts. In hearts 
stressed by ischemia or rapid pacing, administration of DAMGO or DALDA (lO9- 10’7 M) resulted 
in a positive inotropic response accompanied by a decrease in heart rate and coronary flow. Both the 
negative and positive inotropic effects of DAMGO and DALDA wjfere attenuated by the opioid 
receptor antagonist naloxone (10*5M). The negative inotropic effects of p-opioid receptor agonists
“Hieir
in the "unstressed" heart can be influenced by its chronotropic effects. In hearts stressed by ischemia 
or rapid pacing, DAMGO or DALDA improve contractile performance of the heart restoring it to 
its pre-stressed state . The present study demonstrates that the inotropic effects of DAMGO and
DALDA on the isolated heart depend on the pre-existing condition of the heart.
5. The effect of repeated exposure to DAMGO and DALDA and the possible development of 
tolerance to their cardiovascular effects is investigated. In the chronically-instrumented ewe, single 
exposures to DAMGO (0.3mg/kg) or DALDA (0.6mg/kg) resulted in a significant increase in blood 
pressure with DAMGO eliciting a significantly larger response than DALDA. When two doses of 
the same agonist were administered 30 mins apart, the pressor responses to the second doses of both 
DAT .DA and DAMGO was completely abolished. The possibility of cross tolerance between the two 
p-agonists was also investigated. Pretreatment with DAMGO completely abolished the pressor effect 
to DALDA. In contrast, pretreatment with DALDA resulted in a partial though significant 
attenuation of the pressor response to DAMGO. Hence the efficacy of DAMGO and DALDA in 
eliciting cardiovascular responses paralleled their ability to induce tolerance . In the isolated guinea 
pig heart, increasing doses of DALDA (10"n - 10*7M) separated by a 10 min drug washout between 
doses resulted in a dose dependent decrease in the force of contraction. However, when the heart 
was continuously exposed to the same drug treatment for 30 mins without allowing for washouts 
between doses, the inotropic effect of DALDA was completely abolished after 10 mins. This study 
demonstrates acute tolerance to the cardiovascular effects of highly selective p-opioid agonists in 
vivo and in vitro.
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CHAPTER I
A REVIEW OF THE OPIOID SYSTEM
i
1.1 INTRODUCTION
In 1680, Sydenham wrote, “ Among the remedies which it has pleased Almighty God to give man to 
relieve his sufferings, none is so efficacious as opium.” The word opium is derived from the Greek 
name for juice, the drug being obtained from the juice of the poppy, Papaver somniferum. Opium 
contains more than 20 distinct alkaloids. In 1806, a German chemist, Friedrich Sertumer, reported 
the isolation of a pure substance in opium that he named morphine, after Morpheus, the Greek god 
of dreams. This discovery was quickly followed by others such as codeine, discovered by Robiquet 
in 1832 and papaverine by Merck in 1848. By the middle of the nineteenth century, the use of pure 
alkaloids rather than crude opium preparations began to spread throughout the medical world.
The nature of the mood changes produced by opium has been the basis for its non-medicinal use and 
abuse. The unrestricted availability of opium that prevailed until the early years of the twentieth 
century coupled with the invention of the hypodermic needle led to the parenteral use of morphine 
which lead to a severe variety of compulsive drug abuse. The term “opioid” refers to any directly 
acting compound whose effects are stereospecifically antagonized by naloxone. The problem of 
addiction to opioids stimulated a search for potent analgesics free of addictive potential. Prior to and 
following World War n, synthetic compounds such as meperidine and methadone were introduced 
into clinical medicine, but proved to have typical morphine-like actions. Nalorphine, a derivative of 
morphine, was an exception. Nalorphine antagonized the effects of morphine and was used to reverse 
morphine poisoning in the early 1950’s. In addition, its unusual pharmacological profile ushered in 
the development of new drugs, such as the relatively pure antagonist naloxone and compounds with
2
mixed actions (e.g., pentazocine, butorphanol, and buprenorphine). Such agents enlarged the range 
of available therapeutic entities and provide tools needed to explore the mechanisms of opioid actions.
The concept of pharmacologically relevant receptors was first elaborated by Beckett and Casy as 
early as 1954. Portoghese (1965) suggested the concept of different modes of interaction of 
morphine and other analgesics with opioid receptors. Goldstein and coworkers/( 1971) subsequently 
proposed that radiolabelled compounds might be used to demonstrate the existence of these receptors 
and to characterize them. Therefore, as soon as radioligands with high specific activities were 
available, three different groups, independently, but simultaneously, showed that there are 
stereospecific opioid binding sites in mammalian brain (Pert and Snyder, 1973; Simon et al, 1973; 
Terenius, 1973). Opioid receptors have also been identified in various parts of the periphery such as 
the vagus nerve (Young et al, 1980; Zarbin et al, 1990), sympathetic nerve terminals in the heart 
and blood vessels (Mantelli et al, 1987) and the sympathetic lateral columns of the spinal cord 
(Goodman et al, 1980; Romagnano and Hamill, 1984).
Although it was becoming clear by the mid-1960’s that the actions of opioid agonists, antagonists and 
mixed agonist-antagonists could be explained best by actions on multiple opioid receptors 
(Portoghese, 1965), the first convincing evidence for this concept was provided by Gilbert and Martin 
in 1976. Their behavioral and neurophysiological observations in the chronic spinal dog led these
3
authors to propose the existence of three types of opioid receptors. These receptors were named 
after the drugs used in the studies: mu (p, for morphine), kappa ( k , for ketocyclazocine) and sigma 
(o,for SKF 10,047). Various preparations of the isolated ileum of the guinea pig and of the vas 
deferens from mouse; rat, rabbit and hamster have been used for more than 30 years in 
pharmacological assays to assess the agonist/antagonist properties of opioids (Kosterlitz et al, 1980; 
Kosterlitz et al, 1981; Wild et al, 1993). Whereas morphine is more potent than the enkephalins 
in inhibiting neurotransmitter release giving rise to electrically induced contractions of the guinea pig 
ileum, the reverse is true in the mouse vas deferens preparation. Moreover, the effects of the opioid 
peptides on the vas deferens are relatively insensitive to naloxone. Based on these observations, 
Kosterlitz and coworkers proposed that a fourth type of opioid receptor, named delta (ô  for 
deferens), is present in mouse vas deferens (Lord et al, 1977). The a receptor was subsequently 
shown to be non-opioid in nature, thus there are three main types of pharmacologically defined opioid 
receptors: p, ô  and k . Their existence has recently been clearly confirmed using molecular biology 
techniques; three types of opioid receptors have been cloned, with binding and functional properties 
consistent with their identities (Reisine and Bell, 1993; Kieffer, 1995; Satoh and Minami, 1995). 
Pasternak and coworkers (1986) subsequently reported the identification of two subtypes of the p- 
receptor. The p-receptor is thought to be a high affinity-binding site for morphine and opioids 
responsible for supraspinal analgesia while the p—receptor is a low affinity site responsible for other 
actions such as spinal analgesia and respiratory depression.
4
By the mid-1970’s, the first endogenous peptide ligands for opioid receptors (enkephalins and 0- 
endorphin) were isolated and sequenced (Hughes et al, 1975; Bradbury et al, 1976; Li and Chung, 
1976). Another group of peptides, the first of which was named dynorphin, was then identified in 
the 1980’s (Goldstein et al, 1981). The endogenous opioid peptides are encoded by different genes, 
expressed in distinct neuronal pathways or cell types, and have differing selectivities for the various 
classes of opioid receptors. In the same period, it was recognized that each of the opioid peptides 
is made as part of a larger precursor protein. In mammals, there are three such precursors: 
proenkephalin A, which yields four met-enkephalins, one leu-enkephalin, one met-enkephalin-Arg6 - 
Phe7 and one met-enkephalin-Arg6-Gly7-Leu8 (Noda eta l, 1982); prodynorphin (or proenkephalin 
B), which gives rise to dynorphins A and B, and a- and P-neoendorphins (Kakidani et al, 1982; Noda 
et al, 1982); and proopiomelanocortin, which is processed into corticotropin, P-lipotropin and 
melanotropins along with P-endorphin (Nakanishi eta l, 1979).
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Fig. 1 Non-selective agonists and antagonists at opioid receptors
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Table 1. Endogenous Ligands of Opioid receptors
Mammalian peptides
Enkephalins Met5-enkephalin: Tyr-Gly-Gly-Phe-Met Leu5-enkephalin: Tyr-Gly-Gly-Phe-Leu 
Met5-enkephalin-Arg6-Phe7: Tyr-Gly-Gly-Phe-Met-Arg-Phe 
Met5-enkephalin-Arg6-Gly7-Leu8: Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu
Dynorphins
Dynorphin A:Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Trp-Asp-Asn-Gln 
Dynorphin B:Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr '
: „ z - ; ^  \ Asii-Vsi
P-neoendorphin Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
P-endorphin Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-ltjr-
Endomorphin-1 Tyr-Pro-Trp-Phe-NH2
Endomorphin-2 Tyr-Pro-Phe-Phe-NH2
Amphibian peptides 
Demorphins
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NHz
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Lys
Tyr-D-Ala-Phe-Trp-Tyr-Pro-Asn
Deltorphins
A: Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 (deltorphin, dermenkephalin,dermorphin 
gene- associated peptide)
B: Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II)
C: Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I)
7
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Endorphins, enkephalins and dynorphins, which all have the amino-acid sequence Tyr-Gly-Gly-Phe, 
bind with low to moderate specificity to the three opioid receptors. P-endorphin binds to the p and 
Ô receptors with comparable affinity, but because of their selectivity, Met- and Leu-enkephalin are 
considered to be the endogenous ligands for the ô receptor and dynorphins for the K-opioid receptor. 
Until very recently, there was no known mammalian peptide that displayed both high affinity and 
selectivity for the p receptor. A study just published describes the discovery and isolation of two 
peptides from the brain named endomorphin-1 (Tyr-Pro-Trp-Phe-NFQ and endomorphin-2 (Tyr-Pro- 
Phe-Phe-NLQ (Zadina etal, 1997). The high affinity (ki = 360pM) and selectivity (4000 and 15000 
fold preference over the ô and k receptors) of these peptides for the p receptor make them very likely 
candidates for its natural ligands.
Though well defined, the nomenclature of the opioid receptors is rather confused for the following 
reasons: (a) although the use of Greek letters is generally accepted by pharmacologists, molecular 
biologists renamed the p - ,ô -  and K-opioid receptors MOR, DOR and KOR respectively; (b) both of 
these nomenclature are poorly informative regarding the nature of these receptors. For instance, the 
Greek letters p and k , derived from synthetic ligands (morphine and ketocyclazocine, respectively), 
provide no information on the endogenous agonists acting at these receptors. Similarly, the 
nomenclature proposed by the molecular biologists is equally unsatisfactory because it is derived from
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the Greek letters. Based on the guidelines defined by the International Union of Pharmacology 
(IUPHAR) Committee on Receptor Nomenclature and Drug Classification, receptors should be 
named after their endogenous ligands and identified by a numerical subscript corresponding to the 
chronological order of the formal demonstration of their existence by cloning and sequencing 
(Vanhoutte etal, 1996). Thus, the generic designation for these receptors on which all opioids act 
as agonists should be OP. Because the ô receptor was the first to be cloned (Evans et al, 1992; 
Kieffer etal, 1994), it should be correctly named OPl5 and the k and p receptors, which were then 
successfully cloned (Reisine and Bell, 1993; Kieflfer, 1995; Satoh and Minami, 1995), should become 
the OP2 and OP3 receptors, respectively. This new nomenclature unlike the other two used in the 
literature to date, would allow any newly discovered opioid receptor(s) to be logically named 
following the same informative guidelines.
9
1.2 CHARACTERIZATION OF OPIOID RECEPTORS 
1.21 Agonists and antagonists at ô (OP,) receptors
With few exceptions, all ô receptor agonists are peptides, derived from enkephalins or belonging to 
the class of amphibian skin opioids (table 1). D-Ala2-D-leu5-enkephalin (DADLE) was initially found 
to be a selective agonist at ô receptors using guinea pig ileum and mouse vas deferens assays 
(Kosterlitz etal, 1980). However, receptor-binding studies subsequently showed that DADLE has 
only a two-fold greater affinity for ô than for /A receptors (James and Goldstein, 1984). A 
hexapeptide, DSLET (fig 2), was found to have at least 20-600-fold selectivity, depending on the 
assay, for ô over k  and p receptors. More recently, novel opioid peptide agonists have been 
synthesized: DSTBULET (fig 2), and its analogues BUBU (fig 2) (Delay-Goyet et al, 1988) and 
BUBUC (fig 2) (Gacel et al, 1990), which are up to 1000-fold more potent at ô than at m 
receptors. The cyclic peptides DPDPE and DPLPE (fig 2) and derivatives are of comparable 
selectivity for the ôreceptors (Mosberg etal, 1983; Toth et al, 1990). Certain opioid peptides such 
as deltorphin (Kreil et al, 1989) from the amphibian skin also have high affinity and selectivity at ô 
receptors. * 0
The first non-peptidic agonist that was reported to have some selectivity for ô opioid receptors was 
BW373U86 (fig 2) and although this compound is only approximately 20-fold more potent at ô than 
at k  or p receptors (Chang etal, 1993) as well as exhibiting a degree of toxicity, it could represent
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a lead compound for the development of non-peptidic ô receptor agonists. Indeed, the methyl ether 
of one enantiomer of BW373U86, SNC 80 (fig 2) (Bilsky et al, 1995), has been recently synthesized, 
and its properties are promising. Studies with SNC80 have demonstrated a 2000-fold selectivity for 
Ô over ji receptors. Furthermore, in contrast to BW373U86, SNC 80 exhibits only minimal signs 
of toxicity (Bilsky e/a/., 1995).
The naltrexone derivative naltrindole (NTI) was the first really selective and potent ô receptor 
antagonist to be synthesized (Portoghese et al, 1988). It binds to ô receptors in monkey brain with 
a kj value in the picomolar range and a 1 0 0 -fold selectivity for these receptors as compared with p 
and k  receptors (Emmerson et al, 1994). Substitution of tetrahydroisoquinoline (Tic) at the 2- 
position of a deltorphin -related tetrapeptide analogue produced a potent and highly selective ô 
receptor antagonist, TIPP (fig2) (Emmerson et al, 1994; Schiller et al, 1992). The Iq of TIPP was 
found to be approximately 1 nM making it less potent than NTI, but its selectivity for ô receptors 
is 80-fold higher than that of the non-peptide antagonist (Emmerson et al, 1994; Schiller et al,
1992). Reduction of the Tic2-Phe3 peptide bond in TIPP resulted in TIPP[Y] (fig-3), which shows 
improved ô antagonist potency and selectivity, and p or k antagonist properties (Schiller et al,
1993).
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Fig. 2 8-opioid receptor agonists
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Fig. 3 8-opioid receptor antagonists
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1.2.2 Agonists and antagonists at k  (OP2) receptors
The first really selective k  agonist, the arylacetamide U-50,488 (fig 4) was synthesized in 1982 by 
the Upjohn Company (Lahti et al, 1982; Vonvoigtlander et al, 1983). It was followed by 
compounds U-69,593 (Lahti et al, 1985) and U-62,066 (Vonvoigtlander and Lewis, 1988) with 
comparable or higher k selectivity. Several other agonists have been synthesized as derivatives of 
this first series of arylacetamide compounds. These include PD 117302 (Vonvoigtlander et al, 1983; 
Clark etal, 1988), CI-977 (Hunter et al, 1990) ICI 197067, ICI 199441 and ICI 204448 (Costello 
etal, 1988; Nock et al, 1989). HMD 61753, and to a lesser extent, EMD 60400 are also selective 
k  receptor agonists acting at the periphery (Barber et al, 1994a; Barber et al, 1994b)/ arb)7^A series 
of benzeneacetamido-piperazine analogues, such as GR 89696, are also potent and rather selective 
k  receptor agonists (Hayes et al, 1990; Rogers et al, 1992).
Various structural modifications have been made in dynorphin molecules in attempts to synthesize 
analogues with enhanced selectivity for the k  receptors. Thus, [D-Pro10]dynorphin A -(l-ll) was 
shown to be about 200-fold more potent than U-50,488 in stimulating k  receptors (Gairin et al, 
1984). Shorter (E-2078) and longer dynorphin A analogues with potent and selective k  agonist 
properties have also been described.
The first compounds designed for blocking k  receptors, such as TENA (fig 5), lacked sufficient
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selectivity (Kosterlitz etal, 1981). However, the concept of bivalent ligands, used for the synthesis 
of TENA, led to the morphine derivative nor-binaltorphimine (nor-BNI) (Portoghese et al, 1987), 
which has a IQ value for inhibiting [3H]U-69,593 binding to monkey brain membranes of 60pM, and 
a 100-fold and 200-fold preference for k  over and : receptors respectively (Emmerson et al,
1994). However, in vivo, nor-BNI exhibits an unusually long duration of action as k  receptor 
antagonist (Horan etal., 1992) and its k selectivity has been questioned (Birch et al, 1987; Levine 
etal, 1990). More recently, Olmsted et al. (1993) (Olmsted eta l, 1993) synthesized a new series
tAtoS
of NTI derivatives, among which 5'-[N -(butylamidino)-methyl] NTI revealed to be more potent than 
nor-BNI to block k  receptors. In addition, this compound exhibits a 57-fold and 90-fold preference 
for k over p and 5 receptors respectively (Olmsted et al, 1993).
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Fig. 4 K-opioid receptor agonists
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Fig. 5 K-opioid receptor antagonists
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From Raynor et al., Mol Pharmacol. 45: 423-428, 1994a
Mcknight and Rees, Neurotransmissions, 7:1-7, 1991
1.2.3 Agonists and antagonists at \l (OP3) receptors
To date, the most potent and selective agonist at p receptors is the benzimidazole opioid etonitazine 
(fig 6 ), with a Kd value of 20pM for m receptor binding sites in monkey brain membranes, and p:K 
selectivities of about 9000 and 12,000 respectively (Emmerson et al, 1994).
FK 33,824 (fig 6 , (Roemer et al, 1977) was the first peptide analogue of met-enkephalin with high 
affinity for the p receptor, and p.K selectivity of approximately 30, to be synthesized. The related 
compound DAMGK) (fig 6 , also referred to as DAGO or DAGOL, (Handa et al, 1981), which has
A
become the most commonly used selective p receptor agonist., is almost 1 0  times more selective than 
FK 33,824 and has high affinity (Kd = 0.7nM) for the p receptor. These properties led to the 
development of [3H]DAMGO for the selective labeling of p receptors in membranes or section from 
various tissues.
Naloxone, the first opioid receptor antagonist identified, has higher affinity for the p receptor than 
for the other opioid receptors (Magnan et al, 1982; Emmerson et al, 1994). Naltrexone is less p 
receptor selective (Magnan et al, 1982; Emmerson et al, 1994) but has a greater potency and longer 
duration of action than naloxone (Crabtree, 1984). Other long-lasting p receptor antagonists are 
naloxazone and naloxonazine (fig 7). The fiimarate methyl ester derivative of naltrexone, P- 
funaltrexamine (P-FNA) (Portoghese e ta l, 1980), acts as an irreversible p receptor antagonist, but
18
also as a reversible k  agonist. More recently developed derivatives of naltrexone and 
dihydromorphinone (fig 7 ), appear to be selective irreversible antagonists at p. receptors without any 
agonistic action at other opioid receptors (Jiang et al, 1994).
Antagonists with the highest selectivity towards p receptors are cyclic peptides related to 
somatostatin. The most frequently^ compounds are CTAP and CTOP (fig 7) which inhibit 
[3H]naloxone binding to rat brain membranes with an IG50 value of about 3nM and have a 1 2 0 0 - and 
4000-fold selectivity for the p  receptors versus the k  and 5 receptors. The more recently developed 
analogue D-Tic-CTOP (TCTOP) has about 10,000-fold higher affinity for p  receptors than for Ô 
receptors (Kazmierski et al, 1988).
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Fig. 6 |i-opioid agonists
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Fig. 7 |I-opioid antagonists
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From Raynor et al., Mol Pharmacol. 45: 423-428, 1994a
Mcknight and Rees, Neurotransmissions, 7:1-7, 1991
Table 2. In vitro opioid peptide activity profile
Bioassay Binding (nM)
Peptide analog GPI MVD Kip Ki 5 K iW
Tyr-Gly-Gly-Phe-Met 6.7 1.5 9.5 0.91 0.095
Tyr-D-Ala-Gly-NMePhe-Gly-ol (DAMGO) 4.5 33 1 .0 345 345
Tyr-D-Pen-Gly-Phe-D-Pen (DPDPE) 2350 2 .8 710 2.7 0.004
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 1.4 2.4 0.7 62 8 8 .6
Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2(DELT) 845 0.147 262 1.44 0.005
Tyr-D-Arg-Phe-Lys-NH2 (DALDA) 254 781 1.69 19200 11400
Tyr-D-Nva-Phe-Om-NH2 (TNPO) 104 271 1.17 2 2 0 0 1880
GPI: Guinea pig ileum MVD: Mouse Vas Deferens
Functional and binding assays demonstrating the affinity and efficacy of opioid peptide 
analogs at p- and 5-opioid receptors.
/ Adapted from: Schiller et al., Proc. Natl. Acad. Sci. U.S.A. 89: 11871-11875,1992. 
Schiller et al., J. Med. Chem 32: 698-703, 1989.
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1.3 DISTRIBUTION OF OPIOID RECEPTORS
Similar distribution patterns of receptors have been obtained using autoradiographical techniques with 
various tritiated and radioiodinated ligands (Waksman et al., 1986; Delay-Goyet et al., 1990, Renda 
et al, 1993). In the CNS, ô receptors have a more restricted distribution than other opioid receptors. 
The highest ô receptor densities are present in olfactory bulb, neocortex, caudate putamen and 
nucleus accumbens. Recently, antibodies generated against selective portions of the ô receptor amino 
acid sequence were used to localize this receptor type in the CNS of rodents and primates. The 
observed immunohistochemical distribution matched perfectly that established using 
autoradiographical methods (Dado et al, 1993; Bausch et al, 1995; Honda and Arvidsson, 1995). 
In addition, immunocytochemistry at the ultrastructural level (Cheng et al, 1995) provided the 
definitive proof of the existence of presynaptic opioid receptors responsible for the inhibitory 
influence of opioids on the release of neurotransmitters from the terminals of primary afferent fibers 
within the dorsal horn of the rat spinal cord (Bourgoin et al, 1994).
Species differences in the distribution of opioid receptors are particularly striking. For instance, in 
the guinea pig, the highest density of specific sites for the tritiated arylacetamide compounds and 
hence K-receptors is found in the inner layers of the cerebral cortex, the substantia nigra and the 
interpeduncular nucleus. By contrast, in the rat, only low levels of labeling by these radioligands
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are found throughout the cerebral cortex, the highest densities of specific binding sites being observed 
in the nucleus accumbens, claustrum, dorsal endopiriform nucleus and interpeduncular nucleus (Nock 
etal, 1989).
The presence and localization of opioid receptors in the periphery has not been investigated to the 
same extent as in the CNS. The development of the guinea pig ileum and mouse vas deferens as 
models of opiate actions made it possible to directly demonstrate the existence of pharmacologically 
relevant opioid receptor binding sites in the gut (Kosterlitz and Waterfield, 1975; Henderson et al, 
1972). The guinea pig ileum is often used as a bioassay system preferentially for the p-receptor while 
the ô-receptor is pharmacologically characterized using the mouse vas deferens, p - ,  ô- and k -  
receptors are present in a variety of peripheral tissues of most species investigated so far, including 
man (Nishimura et al, 1986). In the rat and guinea pig, autoradiographic studies have shown the 
presence of specific p- and ô-receptor binding throughout the GI-tract (Nishimura et al, 1986). 
Opioid receptors have also been reported in diflferent areas of the vascular system including the heart 
(Krumins et al, 1985)and vagus (Young et al, 1980; Zarbin et al, 1990), sympathetic nerve 
terminals in the heart and blood vessels (Mantelli et al, 1987) and the sympathetic lateral columns 
of the spinal cord (Goodman eta l, 1980; Romagnano and Hamill, 1984)..
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1.4 CLONING OF OPIOID RECEPTORS
Shortly after the isolation of a murine recombinant receptor from the NG108-15 cell line (Evans et
"fW & rccept'C*’"
al, 1992; Kieflfer etal, 1994), several groups reported identical sequences from rat and mouse brain 
(Abood et al, 1994; Bzdegae/tf/., 1993; Fukudae/a/., 1993; Yasuda^a/., 1993). In addition, a
s
human cDNA encoding a 372-amino-acid protein with 93% identity with the mouse and ratA receptor 
has been cloned (Knapp et al, 1994). These clones encoding the % receptors, when compared with 
binding data from studies on transfected cells reveal a fairly consistent picture with the rank order of 
aflSnity for the alkaloids being NTI > diprenorphine > etorphine > bremazocine »  naloxone > 
morphine > U-50,488H. For the peptide ligands, the rank order is as follows: DSLET > DADLE > 
TIPP > DPDPE > DAMGO > morphiceptin.
Several identical cDNA clones have been independently isolated and characterized as encoding the 
k receptor from the mouse (Yasuda et al, 1993), rat (Chen et al, 1993; Li et al, 1993) and guinea 
pig Q&e etal, 1994). Dynorphin and its analogues potently bind to the recombinant receptor while 
enkephalin and P-endorphin have low potency for this receptor. The cloned receptor binds alkaloid 
ligands with the following rank order of affinity: bremazocine > ethylketocyclazocine > U-50,488 > 
naloxone > levorphanol > naltrindole > morphine > and for the peptide ligands, the rank order of 
affinity is as follows: dynorphin A »  P-endorphin l-31 > DPDPE > DAMGO. Based on the high 
affinity for U-50,488 and U-69,593, the cloned k receptor has been proposed to be identical with the
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so called “k/ 1 binding site (Raynor et al, 1994a).
The g receptor has been cloned from the rat (Zastawny et al, 1994) and from the human (Wang et 
al, 1994; Wang et al, 1993). Both enkephalin and p-endorphin potently bind to the recombinant 
p receptor, whereas this receptor has much less affinity for dynorphin.. Its rank order of affinity for 
alkaloid ligands is as follows: bremazocine > ethylketocyclazocine > naloxonazine > naloxone > 
morphine »  > U-50,488 and for peptide ligands is as follows: DAMGO > DADLE > DSLET > 
DPDPE. These binding data are consistent with the known pharmacological profile of p receptors. 
Most of the compounds have similar affinity for the human and the rat p receptors. However, the 
affinities of morphine, methadone and codeine are significantly higher for the human p receptor than 
for the fat p receptor (Raynor et al, 1995).
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Table 3. Ligands of the cloned opioid receptors
Receptor
subtype
Selective Ligands 
Agonists Antagonists
Nonselective Ligands 
Agonists Antagonists
Endogenous
Ligands
DAMGO
Morphine
Methadone
Fentanyl
Dermorphin
CTOP Levorphanol
Etorphine
Naloxone
Naltrexone
P-fNA
CM&ta - _ 
Enkephalin
£>-
Endorphin
EodomorpirtirtS
K Spiradoline 
U50,488H 
Dynorphin A
Nor-BNI Levorphanol
Etorphine
EKC
Naloxone
Naltrexone
Dynorphin A
Ô DPDPE
Deltorphin
DSLET
Naltrindole
NTB
BNTX
Levorphanol
Etorphine
Naloxone
Naltrexone
crtvte-td, z:lcu3 
Enkephalin
Selective, non-selective and the putative endogenous ligands of opioid receptors.
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1.5 TRANSDUCTION MECHANISMS
The functional coupling of the three opioid receptors with G proteins was firmly established several
years ago on the bases that guanine nucleotides diminish the specific binding of agonists and that the
latter compounds stimulate GTPase activity in several preparations (Childers, 1991). The predicted
structures of the cloned, k  and \i receptors clearly confirm that they belong to the superfamily of
seven-transmembrane spanning G protein-coupled receptors (Reisine and Bell, 1993, Uhl et ah, 1994,
Kieffer, 1995; Satoh and Minami, 1995). However, it cannot be completely ruled out that opioids
may also act independently of G proteins. For example, the selective p receptor agonist DAMGO,
modulates a Ca2+-dependent K+ channel independently of G proteins and kinase-mediated mechanisms
in cultured bovine adrenal cells (Twitchell and Rane, 1994). Studies on brain tissue indicated that
stimulation of p and <f receptors can inhibit adenylyl cyclase activity (Polastron et al, 1990).
g
However, in rat olfactory bulb, selective p and , but not k  receptor agonists exert a dual effect on 
adenylyl cyclase activity that is GTP-dependent and pertussis toxin -sensitive. Thus, it is likely that 
opioids have differential actions on the various forms of adenylyl cyclase (Olianas and Onali, 1994; 
Olianas and Onali, 1992).
Stimulation by opioid agonists of the cloned rat and human p receptors expressed in COS and CHO 
cells reduces not only forskolin-stimulated adenylyl cyclase activity but also the production of inositol 
triphosphate, in a naloxone sensitive manner (Wang et ah, 1994; Raynor et ah, 1995). Similarly, in
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transfected cells, stimulation of receptors decreases the accumulation of cAMP resulting from cell 
exposure to forskolin (Evans et al., 1992).
A coupling of opioid receptors with Gs -proteins responsible for excitatory effects of opioid agonists 
on target cells has also been hypothesized (Crain and Shen, 1990). These excitatory opioid 
receptors would be activated by lower concentrations of opioids than the “inhibitory” receptors 
coupled to G0or Gq proteins. However, recent investigations demonstrated that opioid receptors can 
couple with various G0 or G- proteins, and also Gz, but not with Gs.
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1.6 THE CARDIOVASCULAR SYSTEM
1.6.1 Cardiovascular regulation
As early as 1866, the first formulated idea that the cardiovascular system may be regulated by neural 
reflexes was established by Cyon and Ludwig (Cyon and Ludwig, 1866). They showed that electrical 
stimulation of the cephalic end of the depressor nerve in the rabbit causes cardiac slowing and a fall 
in systemic pressure. Although incorrectly concluding that this nerve arose from endings in the heart, 
they recognized the significance of their observations, and a new and valid concept of circulatory 
regulation was bom.
Nearly four decades passed before Koester and Tschermak (1902) proved by degeneration 
experiments that the depressor reflex was not cardiac in origin. They correctly identified the 
distribution of the aortic depressor nerve and introduced the concept that the arterial system 
contained pressure-sensitive regions. In addition, the concept of barosensitivity was implicit in the 
observations of Koester and Tschermak.
1.6.2 Arterial Pressure regulation
Blood pressure is the force exerted by the blood against any unit area of the vessel wall and is almost 
always measured in millimeters of mercury (mmHg). The mean arterial pressure (MAP) is the 
average pressure throughout each cycle of the heartbeat. Arterial pressure is not regulated by a single
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pressure controlling system but instead by several interrelated systems that perform specific functions. 
Any condition that alters either the cardiac output or total peripheral resistance (i.e. the impediment 
to blood flow in the blood vessels) will result in a change in MAP, since MAP is a product of the two 
factors. Thus, both these factors are often manipulated in the control of arterial pressure.
Cardiac output is the quantity of blood pumped into the aorta each minute by the heart and is equal 
to venous return (the quantity of blood flowing from the veins into the right atrium each minute) 
except for a few heartbeats at a time when blood is temporarily being stored in or removed from the 
heart and lungs. Cardiac output = stroke volume x heart rate. The heart plays quite a permissive role 
in the regulation of cardiac output, permitting the output to be regulated at any level up to the limit 
of its pumping capability. Under normal circumstances the major factor determining the cardiac 
output is the rate of venous return.
Heart rate is normally determined by the interrelationship between the intrinsic automaticity of the 
sinoatrial node and the activity of the autonomic nervous system. Sympathetic stimulation increases 
= and parasympathetic stimulation decreases the heart rate.
Another important component in the regulation of blood pressure is the renin-angiotensin system. 
Renin released from the kidney acts on circulating Angiotensinogen to produce Angiotensin I. 
Angiotensin His in turn formed from Angiotensin I in a reaction catalyzed by Angiotensin Converting 
Enzyme (ACE). Angiotensin II has a generalised vasoconstrictor action which acts directly to 
produce a rise in systolic and diastolic blood pressure. The production of renin hence Angiotensin 
I is increased when blood pressure falls therefore helping to maintain blood pressure.
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1.6.3 The Baroreflex
The best known of the mechanisms for arterial pressure control is the baroreceptor reflex. Reflex 
circulatory regulation is carried out by the two baroreceptor systems namely the aortic and carotid 
reflex systems (see-Bvans Downing, 1979). The reflex systems consist of stretch receptors, known 
as baroreceptors, located in the wall of the carotid arteries (carotid sinus) and aortic arch. A rise in 
pressure stretches the baroreceptors and causes them to transmit signals into the central nervous 
system, and “feedback” signals are then sent back through the autonomic nervous system to the 
circulation to reduce arterial pressure. Signals from the carotid sinus are transmitted via the Hering’s 
nerve to the glossopharyngeal nerve (Hering, 1923), while those from the aortic arch are transmitted 
through the vagus nerves (Koester and Tschermak, 1902). Both sets of signals end up in the nucleus 
of the tractus solitarius (NTS). Once the baroreceptor signals reach the NTS, secondary signals 
inhibit the vasoconstrictor center of the medulla and excite the vagal center causing peripheral 
vasodilation and a decrease in heart rate and strength of contraction. Conversely, low pressure has 
opposite effects, reflexly causing the pressure to rise back towards normal.
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1.6.4 CARDIOVASCULAR ADAPTATION TO PREGNANCY
The cardiovascular system undergoes profound changes during pregnancy. The first report on 
maternal cardiovascular function in pregnancy was published in 1915 (Lindhard, 1915) in which he 
observed an increase in cardiac output during pregnancy by as much as 50 percent. However, it is 
only in the last decade that it has become feasible, through the use of modern echocardiographic 
methods combined with Doppler, to fully determine the timing and magnitude of the pregnancy- 
related increase in cardiac output. Thus, several investigators have confirmed Lindhard’s observation 
of an increase in cardiac output to be the case in various stages of pregnancy starting from as early 
as the first few weeks to the late stages of pregnancy (Atkins et al, 1981; Capeless and Clapp, 1989; 
Duvekotefa/., 1993; Robson etal, 1989; Walters et al, 1966). Because cardiac output is elevated 
in pregnancy, peripheral resistance is also decreased (Easterling et al, 1990; Mashim et al, 1987; 
Robson et al, 1989). It should however be pointed out that the magnitude of changes observed 
varies enormously between studies. These differences are thought to be due to a number of reasons 
such as differences in methods and number of subjects used, as well as variations in the reference 
point for baseline data and measurement points during pregnancy.
In addition to changes in cardiac output, an initial rise in heart rate followed by an increase in stroke 
volume has also been reported to occur in pregnancy (Capeless and Clapp, 1989; Duvekot et al, 
1993; Robson et al, 1989). Furthermore, mean arterial pressure is decreased relative to the
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preconceptional reference (Clapp et al., 1988). The increases in both stroke volume and heart rate 
lead to an additional rise in cardiac output. These profound changes may be due, in part, to structural 
changes in the heart during pregnancy. There is an increase in left ventricular mass during pregnancy 
(Capeless and Clapp, 1989; Katz et al, 1978; Robson et al, 1989), suggesting a presence of 
myocardial hypertrophy. Left atrial diameter, which has been demonstrated to correlate well as an 
indirect estimate of vascular filling state (Duvekot et al, 1994), has been shown to increase gradually 
through the progressive stages of pregnancy (Duvekot et al, 1993; Katz et al, 1978; Robson et al, 
1989; Vered etal, 1991). This pattern of increase in the left atrial diameter, suggests a rise in both 
preload and circulating blood volume, and in fact closely follows the rise in blood volume during 
pregnancy (Duvekot et al, 1994). It would seem, that the hemodynamic demands in pregnancy are 
consistent with the effects of chronic strain put upon the heart as the structural cardiac changes 
observed in pregnancy, though brought about by different mechanisms, are comparable to those seen 
in athletes undergoing physical training (Robson et al, 1989).
The role of the pregnancy hormones, such as estrogen, progesterone, prolactin, human chorionic 
gonadotropin (hCG) and human placental lactogen (hPL) in the altered cardiovascular state of 
pregnancy cannot be ruled out as yet and remains to be fully elucidated. In man, the guinea pig and 
ewe, estradiol administration has been shown to produce physiologic evidence of ventricular and 
vascular remodeling (Katz et al, 1978; Robson et al, 1989).
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Pregnancy-induced change in baroreflex homeostasis is an area that has received a lot of attention 
in recent years. Not surprising, since the state of pregnancy poses challenges to arterial pressure 
regulation such as in pregnancy-induced hypertension and hemorrhage, a normal consequence of 
every delivery. The methods used to investigate the baroreflex include generation of curves to 
examine the relationship between arterial pressure and heart rate in response to a pressor or depressor 
stimulus. The numerous reports on the status of baroreflex sensitivity in pregnancy are however, 
conflicting. Several investigators report a decrease in baroreflex sensitivity (Tabsh et al, 1986; 
Olsson etal, 1987; Brooks and Keil, 1994a) while others report an enhanced baroreflex sensitivity 
(Seligman, 1971; Magness and Rosenfeld, 1988; Conrad and Russ, 1992). Some of the conflicts in 
these reports may be due to the fact that only the bradycardic responses to increases in arterial 
pressure was examined in some studies, while the entire baroreflex was examined in others. Other 
sources of conflict in baroreflex investigations include the use of anesthesia in some studies, which 
can itself, compromise cardiovascular function. In one study, changes to the bradycardic response 
to a pressor stimulus was compared to overall baroreflex sensitivity in conscious rabbits, and it was 
found that while the former appeared to be enhanced in pregnancy, the latter was significantly blunted 
(Brooks et al, 1995), emphasizing the importance of examining the entire baroreflex curve when 
evaluating differences in pregnancy.
Hormones have also been implicated in the altered status of baroreflex sensitivity seen in pregnancy.
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Studies indicate that reflex increases in vasopressin, adrenocorticotropic hormone (ACTH) and 
glucocorticoids are also blunted in pregnant dogs and sheep (Brooks and Keil, 1994a, b, 
Keller-Wood, 1994a, b), suggesting a general blunting of arterial baroreflex activity in pregnancy. 
It is also possible that any of a number of hormones increased in pregnancy, including estrogen, 
progesterone, angiotensin n, atrial natriuretic factor (ANF), testosterone, oxytocin or prolactin, may 
be mediators (see Brooks and Keil, 1994b). There is no information on the role of hormones in 
baroreflex or cardiovascular regulation in general to make a valid conclusion at present, thus further 
studies are required in this area of the physiology of pregnancy.
Despite the numerous reports that are now available on the hemodynamic changes in pregnancy and 
the recent increase in methodological possibilities, the physiological meaning of these changes, as well 
as the mechanisms involved, remain to be understood. Further understanding of the mechanisms 
involved in the cardiovascular changes observed in pregnancy is of utmost importance, especially in 
the field of obstetrical drug development, as vascular changes and altered hormonal milieu in the 
physiology of the pregnant animal may account for differences in its response to vasoactive drugs. 
Furthermore, there is relatively little information regarding the response to opioids in pregnancy. An 
altered response to opioids in pregnancy will play a significant role in the development of opioid 
drugs for obstetrical use.
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1.7 CARDIOVASCULAR EFFECTS OF OPIOIDS
The discovery of endogenous opiate systems precipitated a resurgence of interest in opiate- 
cardiovascular interactions . One of the earlier observations on the biological activity of opiates 
besides analgesia, was the demonstration of potent cardiorespiratory effects of morphine and other 
opiate alkaloids. In the second half of the 19th century full reports on the cardiac, respiratory and 
blood pressure effects of morphine were available (Jackson, 1914). Subsequently, opioid peptides 
and their receptors were found to be present in brain areas important for cardiovascular control, in 
heart, in autonomic ganglia, and in adrenal medulla (Goodman et ah, 1980; Lewis et ah, 1985; 
Schultzberg et al, 1979; Hanbauer et al, 1982). Opioid receptors were shown to be densely 
distributed in the brainstem and hypothalamus in close proximity to cardiovascular centers.
Administration of opioid peptides, intravenously, intracerebrally or applied directly upon brainstem 
areas produce potent cardiovascular responses. The cardiovascular effects of pharmacologically 
administered opioid peptides are complex and dependent upon species, doses, route and site of 
administration, presence or absence of anesthetics and other interactions (Feuerstein, 1985). Hence, 
the presence or absence of anesthetics can change a bradycardic, hypotensive opioid effect into a 
tachycardia and hypertension (Pfeiffer et al, 1983b; Pfeiffer et al, 1983a; Faden and Feuerstein,
1983). Systemic versus central administration results in differences that are often interpreted to 
indicate a lack of penetration in sufficient quantities to the cardiovascular centers in the brain.
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However, this controversy can also be due to opposite effects of the peptide in different brain sites.
For example, pressor and depressor sites were found for morphine and Dala2,D-Leu5-enkephalm IX
(DADL) in neighboring hypothalamic nuclei, which were less than 1mm apart from each other 
(Feuerstein and Faden, 1982). The relationship between opioid peptides and the autonomic system 
suggests involvement of both the sympathetic and parasympathetic nervous systems in the 
cardiovascular actions of these peptides. Activation of the sympathoadrenomedullary axis has been 
implicated in the pressor and tachycardie responses to the mu agonist DAMGO or the delta agonist 
DADL in the conscious rat (Pfeiffer et al, 1983b; Feuerstein eta/., 1983). On the other hand, the 
bradycardic effects of various enkephalin analogs have been attributed to an activation of the vagus 
(Pfeiffer etal., 1982,1983b) although this may also be due to the potent respiratory depressant effect 
(Pfeiffer et a l, 1983a, b; Faden and Feuerstein, 1983). Morphine and enkephalins were found to 
inhibit the bradycardia elicited in response to vagal stimulation (Musha et al, 1989; Weitzell et al,
1984), as well as the release of acetylcholine from rabbit atria (Weitzell et a l, 1984).
«
The heart is known to contain both opioid peptides and opioid receptors (Krumins et a/., 1985; Kiang 
and Wei, 1984). The direct effects of p,ô and K-opioid agonists have been investigated in a variety 
of cardiac systems, though there is disagreement regarding the direction of change. Ô- and k- but not 
H- agonists were found to decrease contractility in rat (Ventura et al, 1992) and hamster (Kasper
etal, 1992) ventricular myocytes. I n  h u m a n  atria strips, p, ô and k-agonists also produced (Llobe
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andLaorden, 1995) negative inotropic effects. The K-opioid agonist U50,488H produced negative 
inotropic effects in the isolated rat heart (Xia et ah, 1994). In contrast the naturally occurring ô -  
opioid agonists leucine- and methionine-enkephalin produced positive inotropic effects in chick 
embryo ventricular cells (Laurent et al., 1985; Laurent et al., 1986). The negative inotropic effects 
of U50,488H were correlated with a decrease in Ca* transient (Ventura et al, 1992). Ventura and 
co-workers (Ventura et al, 1991) demonstrated that a short exposure of myocytes to U50,488H 
resulted in both an increase in Ca* transient and enhancement of the myofilament responsiveness that 
resulted in an increase in contractility while longer exposures caused a depletion of SR calcium 
resulting in a decrease in C% transient and negative inotropic effects. This indicates the level of 
agonist exposure may determine the direction of change and may explain some of the discrepancies 
in the literature. In the isolated rat atria, p, ô  and k-  agonists were shown to reduce the spontaneous 
rate in a naloxone-sensitive manner (Micol and Laorden, 1994). Another study demonstrated the 
p-agonist fentanyl produced negative chronotropic effects in the rabbit sinoatrial node that was 
completely antagonized by the p-opioid antagonist P-FNA (Saeki et al, 1995). A study on the 
effects of leu-enkephalin on the Ca2+ current (7Ca) of L-type Ca2+ channels concluded the negative 
inotropic effects of the opioid peptide are due in part to a reduction in 7Ca. In addition, opioid peptides 
have been shown to inhibit Na+ - K+ and Ca2+ - dependent ATPase activities in bovine cardiac 
sarcolemma (Ventura etal, 1987). As Ca2+ entry into the myocardial cell is thought to be regulated 
by Ca2+ - dependent ATPase (Dhalla et al, 1982), this may explain, the cardiodepressant effects of
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opioids. Although there is some conflict between studies, they clearly show that opioid peptides 
have a primary action on the heart.. However, while there are numerous studies on the effects of 
opioid receptor agonists on cardiac cells, relatively few studies have been done on the direct effects 
of selective opioid agonists in the whole heart isolated from systemic influences.
AIMS OF THESIS PROJECT
The aim of this study is to evaluate the cardiovascular effects of highly selective opioid agonists. This 
study aims to resolve the disagreements from previous studies which arise from the use of anesthesia, 
poorly selective ligands and/or route of administration. The cardiovascular effects of highly selective 
ligands for all three classes of opioid receptors will be examined in vivo. In contrast to the majority 
of studies on opioids, these ligands will be administered systemically and not centrally. All 
experiments will be done without anesthesia in order to avoid its compounding effects on 
cardiovascular function. If any significant cardiovascular effects are observed in vivo, further studies 
will be carried out in vitro using the isolated guinea pig heart in order to investigate the mechanisms 
responsible for the effects observed in vivo. Furthermore, as the long term goal of the laboratory has 
been to develop an obstetrical analgesic that produces minimal side effects to the mother and the 
fetus, the cardiovascular effects of these candidate opioid ligands will be evaluated in pregnancy to 
determine if the physiology of the pregnant animal alters the cardiovascular effects of opioids and if 
these effects could be deleterious to the mother or the fetus. In summary the scope of the study will 
be as follows:
•  Highly selective opioid ligands: DAMGO (p), DALDA (p), U50,488H (k) and DPDPE (5)
•  Awake and unanesthetized animals', chronically instrumented and conscious sheep
•  Systemic administration o f ligands: intravenous administration of drugs
e  Three indices o f cardiovascular function to be measured: Blood pressure, heart rate and
baroreflex sensitivity
•  Comparative studies with pregnant animals
•  Further investigation o f the results observed in vivo with the isolated guinea pig heart.
0
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CHAPTER 2
THE EFFECTS OF HIGHLY SELECTIVE |> AND K-OPIOID 
RECEPTOR AGONISTS ON BLOOD PRESSURE, HEART RATE, 
THE BAROREFLEX, AND THEIR MODIFICATION BY 
PREGNANCY.
41
2.1 ABSTRACT
In order to assess the cardiovascular effects of systemically administered opioid peptides, changes in 
blood pressure and heart rate were observed after intravenous administration of U50,488H (trans- 
3,4-dichloro-N-[2-(l-prrTolidinyl)cyclohexyl]benzeneacetamide), a selective K-opioid receptor 
agonist, and two selective |i-opioid receptor agonists, DALDA (Tyr-D-Arg-Phe-Lys) and DAMGO 
(D - Ala2, A-Me-Phe4, Gly5-ol] enkephalin in nonpregnant and pregnant sheep. Intravenous 
administration of all three agonists (U50,488H (1.2 mg/kg), DALDA (0.3mg/kg) and DAMGO (0.3 
mg/kg)) to the awake sheep resulted in an immediate increase in blood pressure. The pressor 
response to U50,488H was accompanied by an increase in heart rate and both effects were naloxone- 
sensitive. In contrast, there was no accompanying change in heart rate to DALDA or DAMGO. The 
pressor response to DAMGO and DALDA was significantly attenuated in pregnant animals. In 
contrast, there was no difference between the pressor response to U50488H in nonpregnant and 
pregnant sheep, but the tachycardia was more pronounced in pregnant animals. It was hypothesized 
that the lack of a reflex bradycardia to the pressor responses of both the p- and K-opioid receptor 
agonists was due to a blunting of baroreflex-mediated bradycardia. The reflex bradycardia to 
norepinephrine (0.6 pg/kg/min) was significantly reduced in the presence of DAMGO but not 
U50,488H. In view of the lack of effect of U50,488H on the baroreflex, it was further hypothesized 
that the tachycardia it elicited was due to an increase in sympathetic activity. Pretreatment with 
propranolol (0.1 mg/kg) completely blocked the tachycardia elicited by U50,488H. These data
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suggest that the lack of a reflex bradycardia to the pressor response of p-receptor agonists is due to 
a blunting of baroreflex-mediated bradycardia. In contrast, the increase in heart rate caused by 
U50,488H is mediated by sympathetic activation of the heart.
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2.2 INTRODUCTION
A number of studies have demonstrated that \i- and K-opioid receptor agonists elicit significant 
cardiovascular responses (Hassen etal., 1983; Bell et al., 1990; Morita et al, 1987; Ogutman et al, 
1995), while ô-opioid receptor agonists do not appear to modulate cardiovascular function 
(Kiritsy-Roy et al, 1989; Bachelard and Pitre, 1995). Opioid peptide analogs are generally thought 
to have difficulty crossing the blood brain barrier after i.v. administration. In most studies, these 
agonists have been administered directly into the CNS in anesthetized animals and the resulting effects 
interpreted to be centrally mediated. Microinjection of the p-selective agonist DAMGO ([D-Ala2, 
JV-Me-Phe4,Glycol]enkephalin) into the nucleus tractus solitarius (NTS) was found to increase both 
blood pressure and heart rate in anesthetized rats (Hassen et al, 1982) while another study reported 
hypotension and tachycardia (Faden and Feuerstein, 1983). May and colleagues^found 
intracerebroventricular (i.c.v.) administration of DAMGO to the conscious rabbit caused hypertension 
accompanied by an initial bradycardia followed by a tachycardia while U69,593, a K-selective agonist, 
had no effect on blood pressure or heart rate. In a more recent study, bilateral injection of DAMGO 
into the hypothalamic paraventricular nuclei of conscious rats resulted in an increase in blood pressure 
and tachycardia while U50,488H had no significant effect on either blood pressure or heart rate 
(Bachelard and Pitre, 1995).
However, little is known about the effects of systemically administered p - and k-  opioid agonists on
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blood pressure and heart rate regulation. In the present study, the effects of intravenously 
administered \i- and K-receptor agonists on blood pressure and heart rate in awake sheep were 
compared. All three agonists utilized significantly increased blood pressure but were accompanied 
by different heart rate changes. DAMGO and DALDA increased blood pressure without affecting 
the heart rate while U50,488H increased both blood pressure and heart rate. It was hypothesized that 
the lack of a pressor-induced bradycardia to both p- and K-receptor agonists support an inhibition of 
the baroreflex. In this study, there is evidence that p-agonists significantly depressed baroreflex- 
mediated bradycardia while K-agonists had no effect on baroreflex function. In view of the lack of 
effect by U50,488H on the baroreflex, it was further hypothesized that the tachycardia it elicited is 
due to direct sympathetic activation of the heart.
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2.3 MATERIALS AND METHOD
2.3.1 Surgical procedure
Chronic indwelling catheters were implanted in ewes of mixed Western breed in accordance with 
guidelines approved by the Institution for the Care and Use of Animals at Cornell University Medical 
College. Polyvinyl catheters were placed in the distal aorta and inferior vena cava in all animals. All 
catheters were tunneled and exteriorized to the maternal flank and stored in a pouch. Surgery was 
performed with the ewe under intrathecal lidocaine anaesthesia and supplemented with intravenous 
sodium pentobarbital. Intraoperatively, Ig of ampicillin was placed in the peritoneal cavity of the 
ewe. This preparation permitted continuous recording of all above parameters in an unrestrained 
unanesthetized animal.
2.3.2 Experimental Protocol
Experiments were performed a minimum of 5 days after surgery to ensure complete recovery from 
surgical stress. The health status of all animals was regularly monitored by analysis of their blood 
respiratory gases, daily activities, weight and feeding habits. On the day of the study, the ewe was 
placed in a cart with free access to food and water throughout the duration of the study and care 
taken to provide an environment free of external stressful stimuli. The ewe was allowed a period of 
2h to acclimate to the study conditions prior to drug administration. Continuous recording of blood 
pressure and EKG were obtained with a Gould 2800S analog recorder and appropriate amplifiers.
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/Experimental Protocol (continued) j
The sheep were allowed a minimum of five days to adjust to the animal facilities before surgery j
commenced. Feeding of the animals was suspended for 24 hours prior to surgery. Water supply was
maintained throughout this period. Surgery on pregnant animals was carried out around the
gestational age o f  115 -117  days. The gestational age o f  the pregnant sheep at the tune o f  experiments
ranged from 120-135 days. Experiments with nonpregnant sheep consisted of a mix of originally
nonpregnant animals and previously pregnant animals at 5 days post-partum. Control studies showed
there were no differences in the basal blood pressure and heart rate of both groups of nonpregnant
sheep (data not shown) like that observed between pregnant and nonpregnant animals.
Blood pressure was measured with a Baxter micro-pressure transducer coupled to a Gould 
preamplifier. The transducer was calibrated against a mercury column prior to each experiment. 
Heart rate was obtained from the arterial pressure wave and transposed using a biotachometer. To 
avoid postural artifact, the pressure transducer was mounted at the level of the maternal heart on the 
flank of the animal. All amplifier outputs were recorded on a Gould 2800, 8 channel recorder at a 
speed of 2 mm/sec. The precision and accuracy of the entire system was ± 2mmHg for blood pressure
and ± 4  b.p.m. for heart rate.
and stored on FM tape (TEAC XR-310). Heart rate was obtained from blood pressure or EKG by 
use of a Gould Biotach coupler.
2.3.3 Drugs
U50,488H,DAMGO and DALDA (supplied by the National Institute on Drug Abuse, Rockville, 
MD.) were administered as an i.v. bolus at a dose of 1.2 mg/kg , 0.3 mg/kg and 0.6mg/kg 
respectively. These doses were chosen based on rodent studies with DAMGO (Gordon, 1986; 
Randich etal, 1993), as well as preliminary dose ranging studies (0.3 - 0.9 mg/kg for DAMGO and 
DALDA and 0.3 -1.2 mg/kg for U50,488H) carried out in our laboratory. Each animal was allowed 
a minimum of 3 days between drug studies and only received each drug treatment once. In some 
studies, naloxone (gift from the Dupont-Merck Pharmaceutical Co., Wilmington, DE) was infiised 
i.v. (0 .3  mg/kg/h) starting Ih prior to the administration of the opioid receptor agonist and maintained 
for a total of3h.
2.3.4 Drug treatments
To explore the hypothesis that DAMGO and U50,488H cause a blunting of the baroreflex, a 
challenge dose of norepinephrine (0 .6  pg/kg given over 1 min) was administered to the ewe before 
and after the i.v. dose of U50,488H or DAMGO at the time of their peak pressor effect. The dose 
of norepinephrine was determined from preliminary dose range studies (0 .2  - 1 .0  pg/kg) in order to
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produce a pressor response comparable in magnitude to that of U50,488H or DAMGO. 
Norepinephrine was chosen for its short duration of action compared to phenylephrine. In addition, 
the dose of norepinephrine used in this study has been shown to produce similar blood pressure and 
heart rate responses to phenylephrine in the awake sheep (Magness and Rosenfeld, 1988), and to have 
no direct stimulatory actions on the heart (Magness and Rosenfeld, 1988; Assali et ah, 1981; Woods 
et al, 1977). Furthermore, the effects of comparable doses of norepinephrine were found to be 
completely abolished by the alpha antagonist, phenoxybenzamine (Oakes et al, 1980), eliminating 
the possibility of residual beta effects by norepinephrine at these doses.
To test whether the effects of U50,488H on heart rate involved an increase in sympathetic activity, 
propranolol was administered to the ewe by continuous i.v. infusion (0 .1  mg/kg for 1 0  min starting 
5 min before the U50,488H bolus).
2.4 Data analysis.
Blood pressure and heart rate were analyzed using 1 min intervals and control values were averaged 
over 5 min prior to the administration of DAMGO or U50,488H. Mean arterial pressure was 
calculated as the diastolic pressure plus 1/3 of the pulse pressure. For the baroreflex studies, 
measurements of baroreflex gain were carried out according to the ‘steady state’ method described 
by Komer and colleagues (Komer et al, 1974). Blood pressure and heart rate were determined every
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5s and averaged over 20 seconds for a total of 6  consecutive minutes (2 min before and 4 min after 
norepinephrine administration). Maximum heart rate and blood pressure changes were observed 
60-100s after onset of norepinephrine infusion and the baroreflex gain was calculated as the ratio of 
the decrease in heart rate to the rise in mean blood pressure (bpm/mmHg).
2.5 Statistical analysis
All data are reported as mean ± S.E.M. One-way analysis of variance (ANOVA) with repeated 
measure (factor = time) was used to examine the effects of U50,488H and DAMGO on blood 
pressure and heart rate. In cases where test of normality failed, ANOVA by ranks was used. 
Dunnett's test was used for post-hoc comparison of each time point to the pre-drug control. The 
ability of propranolol to modify the heart rate response to U50,488H was evaluated using Friedman's 
two-way ANOVA with repeated measure (factors = treatment, time). The effects of norepinephrine 
on blood pressure and heart rate before and after the i.v. bolus of U50,488H or DAMGO was 
compared using paired t-tests. Differences were considered significant when P  <0.05.
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2.6 RESULTS
2.6.1 Effects of DAMGO in nonpregnant and pregnant animals.
Mean blood pressure and heart rate in nonpregnant animals prior to DAMGO administration were
81.2 ± 3.2 mmHg and 87.6 ± 1.3 bpm, respectively (n = 4). Intravenous administration of DAMGO 
(0 .3  mg/kg) to the nonpregnant ewe resulted in an immediate increase in blood pressure with no 
change in heart rate (Fig. 8 ). The effect of DAMGO on mean blood pressure was highly significant 
(P < 0.001), and post-hoc comparison revealed that mean blood pressure was significantly elevated 
compared to pre-drug values for up to 15 min. Pretreatment with naloxone completely blocked this 
pressor response to DAMGO (Fig. 9).
Basal mean blood pressure was lower (74.4 ± 1 .8mmHg) and heart rate was higher (99.8 + 4.0 bpm) 
in the pregnant animals (n = 4). The same dose of DAMGO (0.3mg/kg) significantly increased blood 
pressure (P < 0.01), and the effect lasted 11 min after injection (Fig. 8 ). However, the response in
t
pregnant animals was significantly less compared to nonpregnant animals (P = 0.01). This pressor 
response was completely blocked by naloxone pretreatment (Fig. 9). In the pregnant animals, there 
was a tendency for heart rate to decrease after DAMGO administration, although the changes did not 
reach statistical significance (fig. 8 ).
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2.6.2 Effects of DALDA in nonpregnant and pregnant animals
In nonpregnant animals, control mean blood pressure and heart rate were 76.1 ± 1.3 mmHg and 78.8 
±3.1 bpm, respectively (n= 5). The administration of DALDA resulted in a significant increase in 
' mean pressure (P< 0.001), with peak effect occurring slightly later, and being mor-e-significantly 
smaller, than after the same dose of DAMGO (Fig. 10). The peak increase in blood pressure was 
only 32.2 ± 4% over control values. Heart rate did not change appreciably after DALDA 
administration. The pressor effect to DALDA was also completely blocked by naloxone 
pretreatment, fbata *ot
In pregnant animals, mean blood pressure increased from 70.3 ± 2.9 mmHg to 8 6 .1 ± 3.5 mmHg at 
2 min, representing an increase of 18.1 ±3.1% which is significantly less than in nonpregnant animals 
(Fig. 1 0 ). This increase in pressure was completely abolished by naloxone (results not shown).
2.6.3 Effects of U50,488H in nonpregnant and pregnant animals
Intravenous administration of U50,488H (1.2 mg/kg) to the ewe resulted in an immediate increase 
in blood pressure in both nonpregnant and pregnant animals which was longer-lasting than that after 
DAMGO or DALDA (Fig. 11). Mean pressure increased from 76.5 ±2.1 mmHg to 97.3 ± 4.7 
mmHg (n = 4) in nonpregnant animals (n = 4) which lasted for 15-30min (P< 0 .0 5 )  . Heart rate also 
significantly increased after U50,488H (P < 0.001), This increase in pressor response was highly
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significant and post-hoc comparison revealed that mean blood pressure was significantly elevated 
compared to pre-drug values for up to 30 min. Both the blood pressure and heart rate responses were
CbOfarttTl
completely blocked by naloxone. In pregnant animals (n = 4), mean pressure increased from 72.6 ±
2.0 mm Hg to 98.0 ± 4.2 mmHg. Heart rate was significantly elevated after U50,488H, increasing
from 102.5 ±5.3 bpm to 135.7 ± 8.2 bpm, which is significantly greater than that seen in the 
nonpregnant animals. In contrast to DAMGO, DALDA AND U50,488H, the 5-agonist DPDPE 
(0 .6 mg/kg) had no effect on blood pressure or heart rate (data not shown).
2.6.4 Effects of U50,488H and DAMGO on baroreflex gain.
U50,488H. Norepinephrine alone increased mean blood pressure by 17.0 ± 0.8 mmHg and 
decreased heart rate by 19.4 ± 1.1 bpm. Following the administration of U50,488H, the same dose 
of norepinephrine increased the mean blood pressure by 22.1 ± 0.6 mmHg and lowered the heart rate 
by 27.7 ±2.6 bpm (Fig. 12). The calculated baroreceptor gain with norepinephrine was -1.2 ±0.1 
bpm/mmHg before and -1.3 ±0.1 bpm/mmHg after the administration of U50,488H. Comparison 
by the paired t-test showed there was no significant difference in the baroreceptor gain before and 
after U50,488H.
DAMGO. Norepinephrine alone increased mean blood pressure by 15.0 ± 2.7 mmHg and decreased 
heart rate by 20.3 ± 1.5 bpm. In the presence of DAMGO, norepinephrine increased mean blood 
pressure by 17.1 ± 2.2 mmHg and heart rate fell by 10.5 ± 1.6 bpm (Fig. 13). The calculated 
baroreceptor gain was -1.5 ± 0.2 bpm/mmHg before DAMGO and -0.6 ± 0.0 bpm/mmHg afterwards.
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Baroreceptor gain was significantly attenuated in the presence of DAMGO (P < 0.05).
2.6.5 Effect of propranolol on the heart rate response to U50,488H.
Administration of propranolol alone had no effect on basal mean blood pressure and heart rate. 
However, pretreatment with propranolol completely blocked the increase in heart rate following 
U50,488H administration (Fig. 14). Two-way ANOVA confirmed that propranolol pretreatment 
significantly altered the heart rate response to U50,488H (P < 0.05 ).
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Fig. 8 Effects of i.v. DAMGO (0.3mg/kg) on mean blood pressure (top panel) 
and heart rate (bottom panel) in nonpregnant and pregnant sheep (n = 4). 
Data are presented as means'S.E.
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Fig. 11 effects of i.v. U50,488H (1.2mg/kg) on mean blood pressure (top panel) 
and heart rate (bottom panel) in nonpregnant and pregnant sheep (n = 4).
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Fig. 13 Effects of NE (0.6gg/kg/min) on mean blood pressure and heart rate 
in the absence and presence ofDAMGO (0.6mg/kg, n = 6).
Data are presented as meansS.E.
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2.6 DISCUSSION
The results of these studies demonstrate a clear difference not only in the cardiovascular response but 
also in the mechanisms involved in the heart rate response to systemically administered p- and k-  
opioid agonists. DAMGO, DALDA and U50,488H produced significant increases in blood pressure 
but had different effects on heart rate. The p-agonists had no effect on heart rate while the k- 
agonist, U50,488H caused a significant tachycardia. The pressor effects of all three agonists and 
tachycardia elicited by U50,488H were sensitive to naloxone. The results of the norepinephrine 
challenge suggest that DAMGO significantly attenuated baroreflex sensitivity, thus explaining the lack 
of a reflex bradycardia despite a significant increase in blood pressure. In contrast, U50,488H did 
not alter baroreflex sensitivity, and the accompanying tachycardia is mediated by sympathetic 
activation of the heart as demonstrated by its sensitivity to propranolol.
The results with DAMGO are different from those previously reported. Gordon (1986) reported that 
i.v. DAMGO produces a profound reduction in arterial pressure and heart rate in urethane- 
anesthetized rats which is naloxone-sensitive. Randich et al. (1993) also found a dose-dependent 
decrease in arterial pressure and heart rate in pentobarbital-anesthetized rats. In contrast to these 
studies, the present study found a significant increase in arterial pressure after i.v. DAMGO 
administration. Since the doses of DAMGO used in the rodent studies were in the same range as the 
present study, this discrepancy is most likely due to the use of anesthesia in the rat studies. In
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conscious sheep, i.v. administration of FK33-824, another p-selective agonist, had no effect on 
arterial pressure (Wang et al, 1989), thus suggesting that the hypotensive action of p-opioid agonists 
may be due to the presence of anesthesia.
A pressor response has been reported after administration of DAMGO into the CNS, however, the 
extent of distribution of these peptides into the CNS after i.v. administration is thought to be very 
limited. A recent study showed that only 0.08% of an i.v. dose of [D-Pen2,D-Pen5]-enkephalin 
(DPDPE), another pentapeptide, was found in the brain at 60 min (Weber et al, 1992). In addition, 
in the present study, i.v. administration of DALDA (Tyr-D-Arg-Phe-Lys), which is extremely polar 
in nature (Schiller et al, 1989), also results in a rapid elevation of arterial pressure. There is evidence 
that the distribution of DALDA across the blood-brain barrier is very slow (Samii et al, 1994) and 
only very weak activity could be detected in the mouse hot plate test l-2 h after subcutaneous 
administration (Schiller et al, 1990). It is therefore likely that these p-selective peptide analogs may 
also produce a pressor effect via peripheral mechanisms. The idea of a peripheral mechanism is 
supported by a recent report which demonstrated that DAMGO exerts direct vasoconstrictive action 
on vascular smooth muscle as well as potentiating the vasoconstrictive action of norepinephrine 
(Parra ef a/., 1995).
The pressor response to systemic administration of vasoconstrictive agents is known to be
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accompanied by a baroreflex-mediated bradycardia (Oakes et al, 1980; Magness and Rosenfeld, 
1988; Assali et al, 1981; Woods et al, 1977) and this was confirmed in the present study with 
norepinephrine. In contrast, there was no change in heart rate in the presence of a comparable 
pressor response to DAMGO. This suggests that DAMGO may be inhibiting the baroreflex and this 
was confirmed by the inhibition of the baroreflex response to norepinephrine. Considerable evidence 
shows that baroreflex activity can be influenced by central administration of opioid peptides (see 
review, (Gordon, 1994). These studies have generally reported a decrease in reflex-mediated 
bradycardia provoked by increases in arterial pressure (Numao et al, 1985; Petty and Reid, 1982; 
Schaz et al, 1980; Yukimura et al, 1981) with the exception of Matsumura et al. (1992) 
(Matsumura et al, 1992) who found enhanced rather than reduced baroreflex sensitivity in rabbits 
after intracistemal administration of DAMGO. Others have also reported a decrease in sympathetic 
nerve activity in response to opioid peptides (Gordon, 1986; Numao et al, 1985). These studies 
suggest that opioids depress baroreflex activity through a central mechanism most likely at the level 
of the NTS. Microinjection of DAMGO into the NTS, was found to reduce the increase in blood 
pressure and heart rate that occurred with bilateral carotid occlusion (Hassen and Feuerstein, 1987). 
Other studies found that aortic baroreflexes were significantly attenuated when morphine (Wang and 
Li, 1988) or DAMGO (Gordon, 1990) was microinjected into the NTS of rabbits or rats, 
respectively. Furthermore, opioid-induced baroreflex inhibition was completely reversed by NTS 
injections of the opioid receptor antagonist naloxone.
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The precise location and mechanism by which systemic administration of p-receptor peptide analogs 
attenuate the baroreflex are not known, but it is likely to be mediated by a peripheral mechanism, 
p opioid receptors located on vagal afférents (Zarbin et al, 1990) may be responsible for the 
mediation of DAMGO effects on the baroreflex. It is also possible that DAMGO causes an 
attenuation of baroreflex sensitivity by modifying the transmission of impulses in efferent pathways, 
resulting in modulation of vagal or cardiac sympathetic activity such as inhibition of acetylcholine 
release by the vagus which would in turn inhibit baroreflex-mediated bradycardia. Opioid receptors 
have been identified in various parts of the periphery such as the vagus nerve (Young et al, 1980; 
Zarbin et al, 1990), sympathetic nerve terminals in the heart and blood vessels (Mantelli et al, 1987) 
and the sympathetic lateral columns of the spinal cord (Goodman et al, 1980; Romagnano and 
Hamill, 1984). The precise location and mechanism by which i.v. DAMGO inhibits the baroreflex 
remain to be investigated.
Relatively few studies have examined the effects ofU50,488H on blood pressure and heart rate and 
the mechanisms involved. Some studies suggest that K-opioid agonists have no effect on blood 
pressure (May et al, 1989; Bachelard and Pitre, 1995) while others reported hypotension (Hall et al, 
1988; Pugsley et al, 1992). Anesthesia was employed in the majority of these studies with the 
exception of Carter and Lightman (1985) who administered U50,488H into the NTS of conscious 
adult rats and found it to produce a significant pressor effect. In the present study, there was clearly
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a significant increase in mean pressure in response to the administration of U50,488H. The 
tachycardia elicited, instead of the expected reflex bradycardia in response to the pressor effect of 
U50,488H, led to the investigation of its effect on baroreflex sensitivity. In previous studies, 
injections of K-opioid agonists into the cistema magna of anesthetized rabbits have been reported to 
increase the sensitivity of baroreflex control of heart rate in response to a rise in arterial pressure, 
while reducing reflex sensitivity when arterial pressure was lowered (Petty and Reid, 1982). In the 
anesthetized adult rat, the pressor effect of U50,488H was accompanied by a decrease in heart rate, 
consistent with a baroreflex response (Carter and Lightman, 1985). In the present study, it was 
found that U50,488H had no effect on the heart rate response to a challenge dose of norepinephrine 
indicating that K-opioid agonists do not inhibit the baroreflex in unanesthetized animals. The 
observed tachycardia further suggests that there is an increase in sympathetic activity, and this was 
confirmed by the complete reversal of the tachycardia by propanoiol. Since U50,488H, unlike 
DAMGO, is highly lipid soluble, the increase in blood pressure and heart rate is most likely due to 
a centrally-mediated increase in sympathoadrenal outflow leading to an increase in vascular resistance 
and cardiac output which in turn causes an increase in blood pressure.
In summary, these data show that systemic administration of p - and k - opioid agonists in the awake 
animal results in cardiovascular effects that are different from the majority of those reported with 
centrally administered agonists and those carried out in the presence of anesthesia. Furthermore, the
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effects of these agonists on heart rate appear to be mediated via different mechanisms. Effects of k- 
opioid agonists on heart rate clearly involve sympathetic activation of the heart while p-opioid 
agonists significantly attenuate baroreflex-mediated bradycardia via a peripheral mechanism which 
warrants further investigation.
Basal blood pressure was reducedm pregnancy and heart rate significantly elevated confirming 
previous reports on cardiovascular changes in pregnancy (Brooks and Keil,1994c; Clapp et al., 1988; 
Keller Wood, 1994b). The effects of DAMGO, DALDA and U50,488H were found to be different 
when compared to nonpregnant animals. The pressor response to DAMGO and DALDA was 
significantly attenuated in pregnancy while pregnant animals had a higher tachycardia in response to 
U50,488H.
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CHAPTER 3
THE SITE AND MECHANISM OF ACTION RESPONSIBLE FOR 
THE ATTENUATION OF BAROREFLEX - MEDIATED 
BRADYCARDIA BY INTRAVENOUS ^-OPIOID AGONISTS
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3.1 ABSTRACT
As previously reported, DAMGO (Tyr-D-Ala-Gly-NMePhe-Gly-ol) and DALDA (Tyr-D-Arg-Phe- 
Lys) caused an increase in blood pressure with no accompanying reflex bradycardia and it was 
consequently demonstrated that DAMGO attenuates baroreflex-mediated bradycardia in chronically 
instrumented and unanesthetized sheep. In order to assess the site and mechanism by which p- 
agonists cause an attenuation of baroreflex sensitivity, further investigations were carried out using 
the highly polar p-agonist DALDA, which has been shown to have a limited ability to cross the blood 
brain barrier. Furthermore, as the long term goal of the laboratory has been to develop these peptides 
for clinical obstetrical use, the effects of these peptides on baroreflex sensitivity in pregnancy were 
also investigated. The reflex bradycardia to norepinephrine (0.4 - 0.6pg / min) was significantly 
blunted in the presence of both DAMGO and DALDA in pregnant and nonpregnant animals. In view 
of the limited ability of DALDA to get across the blood brain barrier, it was hypothesized that the 
blunting of baroreflex-mediated bradycardia by p-agonists occurs at a peripheral site. Pretreatment 
with the quaternary opioid antagonist, naloxone methiodide (0.4 - 0.6 pg/kg/h) completely blocked 
the attenuation of baroreflex sensitivity by DAMGO and DALDA in both nonpregnant and pregnant 
animals. In order to investigate the baroreceptors as a possible site of action as well as address the 
possibility of these drugs exacerbating hemorrhage-induced hypotension in labor and delivery, the 
effect of both p-agonists on baroreflex-mediated tachycardia to a hypotensive stimulus was 
investigated. The reflex tachycardia to sodium nitroprusside (10 pg/kg/min) remained unchanged in 
the presence of DAMGO or DALDA in both nonpregnant and pregnant animals. These data
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suggests that the blunting of baroreflex-mediated bradycardia by DAMGO and DALDA has a 
peripheral site and mechanism. Furthermore, the lack of any effect on baroreflex-mediated 
tachycardia indicates these p-agonists are not acting at the level of the baroreceptors.
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3.2 INTRODUCTION
The laboratory has been investigating the potential use of p and ô-selective opioid peptide analogs 
for pain control during labor and delivery, therefore an understanding of the peripheral effects of 
opioids on baroreflex control is important for the use of these p-selective opioid peptide analogs as 
clinical analgesic agents. This, coupled with the importance of baroreflex control during labor and 
delivery, and the relative lack of information on the effect of p-opioid peptide agonists during 
pregnancy, led to an extension of the investigations into the cardiovascular role of DAMGO and
(cUupT<y ' l )
DALDA in pregnancy. As previously reported, intravenous (i.v.) administration of DAMGO (Tyr-D- 
Ala-Gly-NMePhe-Gly-ol) resulted in a rapid increase in blood pressure with no significant change in 
heart rate in awake sheep (Omoniyi et al., 1998b). The lack of a baroreflex-mediated bradycardia in 
the presence of a significant pressor response suggested that these p-opioid agonists must inhibit the 
baroreflex, although the site and mechanism were not understood. Previous work by numerous 
investigators have shown that opioids can inhibit the baroreflex, and it is generally thought to be 
mediated by opioid receptors in the central nervous system (CNS), especially those in the nucleus 
tractus solitaiius (NTS) (Gordon, 1986). However, a similar pressor effect without bradycardia was 
observed with the i.v. administration of DALDA (Tyr-D-Arg-Phe-Lys-NH2), a p-selective opioid 
agonist that is highly polar because of its 3+ charge at physiologic pH. This led to the suspicion that 
these synthetic opioid peptides may also inhibit the baroreflex via a peripheral mechanism.
To test the hypothesis that DAMGO and DALDA cause a blunting of the baroreflex, heart rate
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responses to changes in blood pressure using norepinephrine (NE) and sodium nitroprusside (SNP) 
were determined before and after i.v. administration of DAMGO or DALDA in both nonpregnant and 
pregnant sheep. In addition, the quartenary naloxone analog, naloxone methiodide, was used to 
demonstrate that these peptide analogs suppress the baroreflex via peripheral mechanisms.
71
3.3 MATERIALS AND METHOD 
Surgical procedure. See 2.3.1
Experimental Protocol. See 2.3.2
3.3.1 Drug treatments
DAMGO and DALDA were administered as an i.v. bolus at a dose of 0.6 mg/kg, and 0.3mg/kg 
respectively. These doses were chosen based on dose- ranging studies (0.3 - 0.9 mg/kg) with both 
agonists carried out in our laboratory (Szeto et al., submitted for publication). Each animal was 
allowed a minimum of 2 days between drug studies and only received each drug treatment once. In 
some studies, naloxone methiodide (provided by NDDA and supplied by Research Triangle Institute, 
Research Triangle Park, NC) was infused i.v. (0.6mg/kg/h) starting Ih prior to the administration of 
DAMGO or DALDA and maintained for a total of 1.5h.
To test the hypothesis that DAMGO and DALDA cause a blunting of baroreflex function, blood 
pressure challenges using ME (0.6 pg/kg for DAMGO and 0.4 pg/kg for DALDA studies) or SNP 
(10 pg/kg) were administered to the ewe to produce hypertensive or hypotensive pressor stimuli 
respectively. Thirty minutes later, an i.v. dose of DAMGO (0.6mg/kg) or DALDA (0.3mg/kg) was 
administered, and the pressor challenges repeated to coincide with the peak pressor effect of each 
p-opioid agonist. The doses of NE used were determined from preliminary dose range studies (0.2 -
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1.Ong/kg) in order to produce a blood pressure response comparable in magnitude to that observed 
with each opioid agonist. The dose of SNP used was based on previous studies in the adult sheep 
(Keller-Wood, 1994a). Both NE and SNP were administered over 1 min by the use of an infusion 
pump. Norepinephrine was chosen over phenylephrine for the pressor challenge due to its shorter 
duration of action compared to phenylephrine. In addition, the doses of NE used in this study have 
been shown to produce similar blood pressure and heart rate responses to phenylephrine in the adult 
sheep (Magness and Rosenfeld, 1988), and to have no direct stimulatory actions on the heart 
(Magness and Rosenfeld, 1988; Assali et al, 1981; Woods et al, 1977). Furthermore, the effects of 
comparable doses of NE were found to be completely abolished by the alpha antagonist, 
phenoxybenzamine (Pfeiffer et al, 1982), eliminating the possibility of residual beta effects by NE at 
these doses.
3.3.2 Data analysis
Arterial blood pressure and heart rate were monitored continuously throughout the study. Mean 
arterial pressure was calculated as the diastolic pressure plus 1/3 of the pulse pressure. Blood 
pressure and heart rate responses to the NE and SNP challenges were determined using 10 sec 
intervals for a total of 220 consecutive seconds (120 secs before and 100 secs after NE or SNP 
administration). Maximum heart rate and blood pressure changes were observed 60-100s after onset 
of drug infusion. The slope of the regression line representing the change in heart rate (bpm) versus 
change in blood pressure (mmHg) was used as an index of baroreflex sensitivity. Because of the delay
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in heart rate responses to changes in blood pressure, heart rate was plotted against the preceding 
blood pressure change according to the ‘ramp’ method of baroreflex sensitivity assessment (Smythe 
eta l, 1969).
3.3.3 Statistical analysis
Regression lines representing the responses to NE and SNP, as well as responses to NE and SNP in 
the presence of DAMGO or DALDA, were plotted for each animal. The slopes of the regression lines 
for each animal before and after opioid agonist treatment were compared using paired t-tests. 
Differences were considered significant when P  < 0.05.
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3.4 RESULTS
3.4.1 Baroreflex sensitivity in nonpregnant and pregnant animals
Fig 15 illustrates the initial differences in baroreflex sensitivity in response to a hypertensive (NE, top 
panel) and hypotensive (SNP, bottom panel) stimulus in a pregnant and nonpregnant animal. 
Baroreflex sensitivity in response to the NE stimulus was significantly enhanced in pregnant animals 
compared to nonpregnant animals (see Table 3). In contrast, reflex sensitivity was significantly 
attenuated in pregnant animals in response to the hypotensive (SNP) challenged t^o-o5)
3.4.2 Effects of DAMGO and DALDA on NE challenge in nonpregnant animals and pregnant 
animals
Fig. 16 summarizes the mean blood pressure and heart rate data before and after DAMGO (top 
panel) or DALDA (bottom panel) in a representative nonpregnant animal while Fig. ITsummarizes 
the blood pressure and heart rate data before and after DAMGO (top panel) or DALDA (bottom 
panel) in a representative pregnant animal. The baroreflex response to the NE challenge was 
significantly attenuated in the presence of DAMGO or DALDA in both nonpregnant and pregnant 
animals (Table 3).
3.4.3 Effects of DALDA on SNP challenge in nonpregnant and pregnant animals .
In contrast to the NE challenge, baroreflex sensitivity to the hypotensive challenge of SNP remained
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unchanged in the presence of DALDA as illustrated by a representative nonpregnant (Fig. 18, top 
panel) and pregnant animal (bottom panel). DALDA had no effect on the heart rate response to SNP 
in either nonpregnant or pregnant animals (see table 3). Baroreflex sensitivity also remained 
unchanged in the presence of DAMGOC^cd4 ncf* -skouon) •
3.4.4 Effect of naloxone methiodide on the heart rate response to NE in the presence of 
DAMGO and DALDA (nonpregnant animals).
The attenuation of the heart rate response to the NE stimulus observed with DAMGO and DALDA 
was completely blocked by naloxone methiodide (NMI) in nonpregnant animals (Table 3). Figure 19 
illustrates the blood pressure and heart rate data for a representative animal after the administration 
of DAMGO (top panel) and DALDA (bottom panel) in the absence and presence of NMI.
3.4.5 Effect of naloxone methiodide on the heart rate response to NE in the presence of 
DAMGO and DALDA (pregnant animals).
The attenuation of the heart rate response to the NE stimulus observed with DAMGO and DALDA 
was also completely blocked by naloxone methiodide (NMI) in pregnant animals (Table 3). Figure 
20 illustrates the blood pressure and heart rate data for a representative animal after the administration 
of DAMGO (top panel) and DALDA (bottom panel) in the absence and presence of NMI.
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TABLE 3 Baroreflex responses to hypertensive (NE) and
hypotensive (SNP) challenges
NONPREGNANT CONTROL + DRUG
STUDY
NP/ PREGNANT P beats/min/mmHg beats/min/mmHg
NE (hypertensive) NP -0.81 ±0.22 -
P -2.08 ±0.40** -
SNP (hypotensive) NP -2.77 ±0.48 -
P -0.53 ±0.04** -
DAMGO + NE NP -1.10±0.35 -0.44 ±0.08*
P -2.18 ±0.48 -0.65 ±0.17*
DALDA + NE NP -1.03 ±0.30 -0.38 ±0.02*
P -2.26 ±0.39 -0.94 ±0.27*
DALDA + SNP NP -2.10 ±0.45 -1.73 ±0.36
P -0.86 ±0.18 -0.96 ±0.20
DAMGO + NE+NM NP -1.24 ±0.32 -0.98 ±0.21
P -2.60 ±0.42 -2.95 ±0.48
DALDA + NE + NM NP -1.77 ±0.40 -1.73 ±0.36
P -2.50 ±0.40 -2.00 ±0.36
NE:Norepinephrine NM: Naloxone Methiodide SNP: Sodium Nitroprusside *P < 0.02 when 
compared to control values. **P < 0.05 when compared to nonpregnant animals. N = 4 to 8 animals 
per study group.
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Fig. 15 Relationship between mean blood pressure and heart rate in response
to a hypertensive (NE, top panel) and hypotensive (SNP, bottom panel) stimulus
in a nonpregnant and pregnant sheep
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Fig. 16 Relationship between mean blood pressure and heart rate
in response to NE in the absence or presence of DAMGO (A) or
DALDA (B) injionpregnant sheep.
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Fig. 17 Relationship between mean blood pressure and heart rate
in response to NE in the absence or presence of DAMGO (A) or
DALDA (B) in pregnant sheep.
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Fig. 18 Relationship between mean blood pressure and heart rate
in response to SNP in the absence or presence of DALDA in a
nonpregnant (A) or pregnant (B) sheep.
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Fig. 19 The effect of NMI on the relationship between mean blood 
pressure and heart rate in response to NE in the absence or 
presence of (A) DAMGO or (B) DALDA in a nonpregnant sheep.
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Fig. 20 The effect of NMI on the relationship between mean blood 
pressure and heart rate in response to NE in the absence or 
presence of (A) DAMGO or (B) DALDA in a pregnant sheep.
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3.6 DISCUSSION
There is considerable evidence to suggest that baroreflex activity can be influenced by opioid agonists 
(Gordon, 1994). Numerous investigators have studied the effect of centrally administered opioids on 
baroreflex function and generally reported a decrease in baroreflex-mediated bradycardia in response 
to increases in arterial pressure (Numao et ah, 1985; Petty and Reid, 1982; Schaz et al., 1980; 
Yukimura et al, 1981). These inhibitory effects on baroreflex function have most often been 
attributed to activation of central p-opioid receptors because agonists relatively selective for ô -  or k- 
opioid receptors either had little or no effect on baroreflex function (Gordon, 1986; Matsumura et al, 
1992; Numao et al, 1985; Petty and Reid, 1982). In the previous study, it was also found that the 
K-opioid agonist, U50,488H, had no effect on the heart rate response to NE in nonpregnant sheep 
(Omoniyi et al, 1998b).
The results of the present study demonstrate for the first time that systemically-administered p-opioid 
peptide analogs can significantly alter baroreflex sensitivity in both nonpregnant and pregnant sheep. 
Interestingly, both DAMGO and DALDA blunted the baroreflex-mediated bradycardia to pressor 
stimuli, but had no effect on the baroreflex-mediated tachycardia to a hypotensive stimulus. These 
results also suggest that, in addition to opioid receptors in the CNS, peripheral opioid receptors may 
also play an important role in inhibiting the baroreflex.
The inhibition of baroreflex function by p-opioid agonists has generally been thought to be mediated
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by opioid receptors in the CNS, particularly at the level of the NTS (Gordon, 1990; Hassen and 
Feuerstein, 1987; Wang and Li, 1988). This is consistent with the presence of endogenous opioid 
peptides and opioid receptors in this area of the CNS (Goodman et ah, 1980; Kalia et al, 1984). 
Hence, several investigators have studied effects of centrally administered opioids on baroreflexes and 
have generally, reported a decrease in baroreflex-mediated bradycardia (Numao et al, 1985; Petty 
and Reid, 1982; Schaz et al, 1980; Yukimura et al, 1981) in response to increases in arterial 
pressure. In contrast, relatively few studies have addressed the effects of systemically-administered 
opioid agonists or the possibility of peripheral opioid-receptor mediated effects on baroreflex function. 
This is generally because opioid peptide analogs are thought to have difficulty crossing the blood brain 
barrier to any appreciable extent. In our studies however, the rapid onset of the response to DAMGO 
led us to believe that its actions were probably peripherally-mediated. This is further supported by 
the lack of a bradycardia to the pressor response induced by DALDA. DALDA is a potent and highly 
selective p-agonist that is very polar because of its 3+ charge at physiologic pH (Schiller et al, 1989), 
and the distribution of DALDA across the blood brain barrier has been shown to be highly restrictive 
(Samii et al, 1994; Schiller et al, 1990). This study demonstrates that DALDA like DAMGO, 
blunted the heart rate response to pressor stimuli. In addition, the effect of DAMGO and DALDA 
on baroreflex function can be completely antagonized by i.v. administration of naloxone methiodide, 
providing support for the hypothesis that peripheral mechanisms are also involved in the modulation 
of baroreflex function by opioids.
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The heart rate response to pressor agents is determined by the underlying autonomic tone, so that 
the predominance of the sympathetic or parasympathetic tone over one another will determine the 
direction of the heart rate response to pressor stimuli. Previous studies on the autonomic control of 
heart rate in the adult sheep demonstrated that the conscious ewe is under parasympathetic dominance 
hence, the heart rate response to the pressor stimulus of agents such as NE is accompanied by a 
baroreflex-mediated bradycardia (Oakes et ah, 1980; Magness and Rosenfeld, 1988; Assali et ah, 
1981; Woods et ah, 1977). This can be contrasted with the sheep fetus which is under sympathetic 
dominance and therefore responds to the pressor stimulus of NE with a tachycardia (Woods et ah, 
1977; Assali N.S. et ah, 1977).
The specific site and mechanism by which systemic administration of p-opioid agonists attenuate the 
heart rate response to pressor stimuli remain to be determined. Baroreceptors located in the carotid 
sinus and aortic arch are responsible for the detection of changes in arterial pressure, resulting in 
afferent impulses to the NTS. The lack of any effect on the heart rate response to a hypotensive 
stimulus suggests DAMGO and DALDA are not suppressing baroreceptor fimction at the level of the 
baroreceptors. It is possible that DAMGO and DALDA are acting to modulate the efferent signal 
from the NTS to the heart, resulting in an attenuated bradycardic response to a pressor stimulus. A 
direct inhibition of vagal activity would explain the lack of effect on heart rate response to a 
hypotensive stimulus which is instead dependent on cardiac sympathetic nerve activity. This 
hypothesis is supported by previous reports that morphine and enkephalins inhibit the bradycardia
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elicited in response to vagal stimulation (Musha et ah, 1989; Weitzell et al., 1984), as well as the 
release of acetylcholine from rabbit atria (Weitzell et al, 1984). In addition, p-opioid receptors have 
also been demonstrated on vagal nerves (Young et ah, 1980; Zarbin et ah, 1990). Although the lack 
of a bradycardia may also be due to enhanced sympathetic activity, and p-opioid receptors have been 
identified on sympathetic nerve terminals in the heart (Mantelli et al., 1987) and sympathetic lateral 
columns of the spinal cord (Goodman et ah, 1980; Romagnano and Hamill, 1984), this is unlikely 
since the tachycardie response to SNP was not enhanced by DAMGO or DALDA
This is the first report on the effects of opioid agonists on baroreflex sensitivity in pregnancy. 
Pregnancy is known to be associated with marked changes in the cardiovascular system at rest. 
Cardiac output, heart rate and blood volume increases, whereas systemic vascular resistance and 
arterial pressure decreases (Weinstock and Rosin, 1984; Oakes et ah, 1980). In addition to these 
changes in the cardiovascular system of the pregnant animal, other studies have also reported a state 
of altered baroreflex sensitivity. However, there is some conflict among investigators regarding the 
direction of change probably arising from differences in the methods employed, animal species 
studied, and the indices used for assessment of baroreflex sensitivity. Hence, attenuated baroreflex 
sensitivities were reported for smaller increases in maternal pressure and peripheral resistance 
produced by decreases in pressure in the isolated carotid sinus of anesthetized pregnant rabbits 
(Omoniyi et ah, 1998b), as well as smaller reflex increases in lumbar sympathetic activity in 
anesthetized pregnant rats (Cox and Bagshaw, 1979). In contrast, bradycardic responses to increases
87
in arterial pressure, were found to be enhanced in pregnancy (Conrad and Russ, 1992; Magness and 
Rosenfeld, 1988). Other indices used for measurement of baroreflex sensitivity include baroreflex- 
mediated changes in renal sympathetic activity as well as reflex-mediated changes in the level of 
plasma hormones such as vasopressin, adrenocorticotropic hormone, cortisol and angiotensin II. The 
use of anesthesia in some of these studies is also a potential source of conflict as demonstrated by 
reports on anesthetic effects on baroreflexes (Cox and Bagshaw, 1979; Murthy et al., 1982). The 
present study revealed pregnant animals had an enhanced heart rate response to the norepinephrine 
stimulus when compared to nonpregnant animals. In contrast, the heart rate response to SNP was 
significantly attenuated in pregnancy. This is consistent with a previous report by Brooks et al., 
(1995) (Brooks et al, 1995) which demonstrated the same phenomenon in pregnant, conscious dogs.
Hemorrhage-induced hypotension is a normal consequence of every delivery, therefore any potential 
use of these peptides in clinical obstetrics would be greatly compromised by deleterious effects on 
baroreflex control. The present study showed that DAMGO and DALDA also inhibited the heart rate 
response to NE in pregnant sheep, and the data suggests that the magnitude of inhibition was greater X  
in pregnant animals. The enhanced baroreflex sensitivity to the pressor stimulus in pregnancy 
observed in this study, may explain why DAMGO and DALDA caused a higher degree of blunting 
in pregnant animals, as there was a greater potential for suppression of reflex sensitivity when 
compared to the nonpregnant animals. Fortunately, neither DAMGO nor DALDA inhibited the heart
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rate response to a hypotensive challenge, thus ruling out the risk of these peptides compromising 
baroreflex control in delivery.
In summary, these data demonstrate for the first time that systemically-administered p-opioid agonists 
suppress baroreflex-mediated bradycardia while having no effect on reflex-tachycardia in nonpregnant 
and pregnant sheep. In addition, the suppression of baroreflex-mediated bradycardia by p-agonists 
occurs via a peripheral mechanism. The specific site and mechanism by which p-opioid peptide 
analogs attenuate baroreflex sensitivity remains to be elucidated.
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CHAPTER 4.
THE DIRECT EFFECTS OF ji-OPIOID AGONISTS ON THE 
ISOLATED AND PERFUSED GUINEA PIG HEART.
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4.1 ABSTRACT
The mechanism behind the pressor responses previously reported for DAMGO and DALDA was 
investigated in vitro using the isolated guinea pig heart. The investigation was based on the 
hypothesis that the increase in blood pressure observed with DAMGO and DALDA in vivo is as a 
result of a direct effect of these p-agonists on the contractility of the heart. Pilot studies revealed 
conflicting results regarding the inotropic effects of DAMGO and DALDA. It was further 
hypothesized that the pre-existing condition of the heart may determine the inotropic effect of mu- 
agonists on the heart. Hence the effects of DAMGO and DALDA on the isolated and perfused 
guinea pig heart were further investigated under four different conditions, two of which were "stress" 
paradigms: (1) Spontaneous heart rate (2) Elimination of chronotropic Punctuations by electrical 
pacing of the heart (3) Low flow ischemia induced by rapid electrical pacing (4) and following 30- 
mins of no flow Ischemia . DALDA (10"11 - 10"9M) caused a dose dependent decrease in the force 
of contraction, heart rate and coronary flow in spontaneously beating hearts. There was a decrease 
in the force of contraction, coronary flow and heart rate at 10*nM DAMGO while subsequent doses 
(10*9- 10'7M) resulted in increases of all three parameters. Elimination of chronotropic effects with 
electrical pacing at spontaneous rate unmasked dose-dependent negative inotropic effects for both 
DAMGO and DALDA (10 "  - 10"7M) that were bigger in magnitude than those observed in the 
spontaneously beating hearts. In hearts stressed by ischemia or rapid pacing, administration of 
DAMGO or DALDA (109 - 10'7M) resulted in a positive inotropic response accompanied by a 
decrease in heart rate and coronary flow. Both the negative and positive inotropic effects of DAMGO
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and DALDA where attenuated by the opioid receptor antagonist naloxone (10'5 M). The negative
-tketlr
inotropic effects of p-opioid receptor agonists in the "unstressed" heart can be influenced by'its- 
chronotropic effects. In hearts stressed by ischemia or rapid pacing, DAMGO or DALDA improve 
contractile performance of the heart restoring it to its pre-stressed state . The present study 
demonstrates that the inotropic effects of DAMGO and DALDA on the isolated heart depend on the 
pre-existing condition of the heart.
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4.2 INTRODUCTION
The inotropic effects of p, ô and K-opioid agonists have been investigated in a variety of cardiac 
systems, however there is disagreement regarding the direction of change, ô- and k- but not p -  
agonists were found to decrease the contractility of rat (Ventura et al., 1992) and hamster (Kasper 
et al, 1992) ventricular myocytes. In human atria strips, p, ô and K-opioid agonists produced (Llobell 
and Laorden, 1995) negative inotropic effects and while the K-opioid agonist U50,488H produced 
negative inotropic effects in the isolated rat heart (Xia et al., 1994), it was found to increase 
contractility in ventricular myocytes (Ventura et al., 1992; Tai et al., 1992). The naturally occurring 
ô-opioid agonists leucine- and methionine-enkephalin were also found to produce positive inotropic 
effects in chick embryo ventricular cells (Laurent et ah, 1985; Laurent et ah, 1986). The majority of 
these studies involved the use of high agonist doses of up to lO^M and this in addition to a relative 
lack of receptor selectivity of most of the agonists studied can make it difficult to determine the 
receptor-specific effects of opioid agonists on inotropy.
There are relatively few studies demonstrating the direct inotropic effects of opioid agonists on the 
heart itself. While the use of isolated myocytes is more useful than multicellular cardiac preparations 
for the purpose of mechanistic studies, the varying conditions under which these studies are carried 
out creates inconsistencies that may affect the inotropic response of the cardiac cell making it difficult 
to scale the findings up to the level of the heart. Furthermore, the contractile state and hence 
inotropic response of the myocardium can be altered by a variety of conditions. In addition,
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myocardial changes such as chronotropic effects can have confounding effects on the direction of 
inotropic changes. In the present study, the effects of the highly potent and selective p-opioid 
agonists DAMGO and DALDA are compared under different inotropic and chronotropic conditions 
of the heart.
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4.3 MATERIALS AND METHODS
4.3.1 Isolated heart perfusion
Female Hartley guinea pigs weighing 350 to 400 g were sacrificed by cervical dislocation under light 
anesthesia with C02 vapor. The rib cage was rapidly dissected away, exposing the heart. A cannula 
was inserted into the aorta and the heart was perfused at constant pressure (40 cm of H20) with 
Krebs-Henseleit solution equilibrated with 95% 0 2 and 5% C02 and maintained at 32°C (pH 7.4). 
The composition of the solution was as follows (in millimolar amounts) : NaCl, 118.1; KC1, 4.8; CaCl2 
2.5;MgS04 2.4; KHfO,, 1.0; NaHC03, 25.0; and glucose, 11.1. The heart was then transferred to 
a Langendorff apparatus, where it was suspended by the aortic cannula and allowed to beat 
spontaneously. The sinus rate was determined from surface electrograms recorded from the right 
atrium and left ventricle and recorded at a paper speed of 25mm/sec on a polygraph (Gould model 
2400). A resting tension of Ig was applied and isometric left ventricular contractile force was 
measured with a force-displacement transducer (Grass FT03C) and continuously recorded on a Grass 
polygraph (model 78). A period of thirty minutes was allowed for stabilization of the heart rate and 
contractile amplitude before drug treatments were applied. For the paced hearts, once mounted, the 
hearts were continuous paced using bipolar platinum electrodes and stimulated with a Grass stimulator 
(model S44) at 2.5Hz with square wave pulses, 0.4 msec in duration and of supramaximal intensity 
(1IV). The frequency of pacing was increased to 5Hz for hearts subjected to rapid pacing. For the 
ischemia-reperfusion studies, following a 30-min pre-ischemic stabilization period, global ischemia 
was induced by 30-min of complete interruption of coronary perfusion. This was followed by a
95
reperfusion period of 1 hour.
Coronary flow waa measured by collecting timed samples of the coronary effluent from the heart.
96
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4.3.3 Drug treatments
"Non-stressed hearts". Following the stabilization period, hearts were perfused with DAMGO or 
DALDA in increasing doses of 10*n , 10'9 and 10‘7M. Each dose was administered for 10 min 
followed by a 10 min recovery period during which the heart was perfused with Krebs-Henseleit 
buffer alone followed by the next dose. In order to eliminate confounding chronotropic effects, dose 
response studies were conducted in hearts paced at spontaneous rate using the same protocol. Only 
one dose response study was carried out per heart.
Arrhythmic hearts. In early pilot studies, several hearts developed arrhythmias due to poor coronary 
perfusion caused by insufficient hydrostatic pressure. Dose response studies were carried out in these 
hearts with DALDA at increasing doses from 10*7 to 10"5Musing the same protocol as described 
above.
"Stressed hearts". Following the stabilization period of 30 min, hearts were subjected to either one 
of two stress paradigms: Rapid pacing at twice the spontaneous rate or complete cessation of 
coronary perfusion, with each lasting for a period of 30 min. The hearts were allowed a further 10 min 
to recover spontaneous rate and contractile amplitude after the completion of the stress paradigm 
before drug administration. Due to the time-related changes that occur in the myocardium following 
ischemia, only one drug dose was administered per stressed heart to allow for interpretation of data. 
The point of administration (10 min post-reperfusion) was chosen to avoid the early disturbances 
brought about by ischemia and late changes from post-reperfusion damage.
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4.4 Statistical Analysis
All data are reported as mean ± S.E.M. One-way analysis of variance (ANOVA) with repeated 
measure was used to examine the effects of DAMGO and DALDA on force of contraction, heart rate 
and coronary flow. In cases where test of normality failed, ANOVA by ranks was used. Dunnett s 
test was used for post-hoc comparison of each concentration to the pre-drug control. The ability of 
electrical pacing of the heart to modify the inotropic and coronary flow response to DAMGO and 
DALDA was evaluated using Friedman's two-way ANOVA. The difference between inotropic 
effects in "stressed" versus "non-stressed" hearts was analyzed using paired t-tests. Differences were 
considered significant whenP < 0.05.
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4.5 RESULTS
4.5.1 Dose Response studies (DALDA)
f
Perfusion with DALDA (10"n - 10"7M) resulted in a significant dose dependent decrease in heart rate
(p < 0.001, Fig. 21). The force of contraction and coronary flow were also significantly reduced (P
< 0.02, Fig. 22). Since the decrease in heart rate may modify any direct action of DALDA on
contractility, additional dose response studies were carried out under constant pacing of the heart at
spontaneous rate. The negative inotropic effect of DALDA was significantly greater in paced hearts
when compared to unpaced hearts (P < 0.03), resulting in a 50% reduction in the force of contraction 
a t
at 10‘7M (Fig. 22). -  ;<v--A
4.5.2 Dose Response studies (DAMGO)
In hearts perfused with DAMGO, the first drug administration (10 nM) resulted in a 34% drop in 
heart rate compared with 15% at the same dose of DALDA (fig. 21). This profound chronotropic 
effect of DAMGO resulted in a rise in the baseline tension of the heart which in turn masked the 
inotropic effects of subsequent doses of DAMGO. Hence the higher doses of 10 *M and 10 7M of 
DAMGO appeared to have smaller effects on the force of contraction, coronary flow and heart rate 
(Fig. 23). When the confounding chronotropic effects of DAMGO was eliminated by pacing, a 
significantly larger, dose-dependent decrease in inotropy (P < 0.001) was unmasked (Fig. 23).
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Similarly to DALDA, the negative inotropic effect of DAMGO in paced hearts (n = 4) was 
significantly greater than in unpaced hearts (P < 0.001), resulting in a 55% reduction in the force of 
contraction at 10'7M.
4.5.3 Arrhythmic hearts
In pilot studies, low flow ischemic hearts resulting from poor coronary perfusion responded with a 
dose-dependent increase in the force of contraction (Fig. 25a, b) following the administration of 
DALDA (10"7- 10'5M). The contractile performance of the heart was significantly increased (P < 
0.002) resulting in a maximum increase of 30% at 10*5M. Furthermore, following the first dose of 
DALDA administered, the arrhythmias resulting from poor coronary perfusion ceased (Fig. 25a)
4.5.4 "Stressed hearts"
Following ischemia or rapid pacing, the force of contraction of the heart was significantly reduced (P 
< 0.05) prior to any drug administration. Perfusion of these compromised hearts with DALDA or 
DAMGO resulted in increases in the force of contraction (Figx27a, b). In ischemic hearts perfused 
with DALDA or DAMGO, the force of contraction was increased by 32% ( P < 0.02) and 53% ( P 
/< 0.03) respectively compared to pre-drug values. In rapidly paced hearts, the force of contraction 
was increased by 52% with DAMGO (P < 0.05) and 64% with DALDA (P< 0.05). The positive 
inotropic effects of both DAMGO and DALDA were also accompanied by decreases in the coronary 
flow and heart rate.
The effect of naloxone on the inotropic response of DAMGO and DALDA in the normal and 
"stressed" heart was inconclusive in the present study. Naloxone at 10‘5M initially appeared to 
attenuate the inotropic effects of DALDA. However, this relatively high dose of naloxone by itself 
produced an inotropic response in the heart.
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Fig. 21 Effects of DALDA and DAMGO on heart rate in 
spontaneously beating hearts (n = 4). Data are presented 
as meansTS.E.
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Fig. 22 Effects of DALDA (10“11-10"7M) on force of contraction (top panel) 
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Fig. 23 Effects ofDAMGO (10'n-10’7M) on force of contraction (top panel) 
and jCoroo*gfw (bottom panel) in spontaneously beating (unpacedj and 
electrically paced hearts (n = 4). Data are presented as means"S.E.
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Fig. 24 Representative traces showing the effect of DALDA 
(10'MM) on the force of contraction in (A) an unpaced heart 
and (B) an electrically paced heart.
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Fig. 25 (A) Representative traces showing the effect of DALDA 
on the force of contraction of the heart in pilot studies. (B) 
Effect of DALDA on % change in force of contraction in pilot 
studies (n = 3).
Control 10*7M lO^ M 10 M
^  60-, 
oTO)
ro 50 -
S
£  40-
Co
30 -
8 20 -
o
10 -
o
LL
■4567-8
Log [DALDA] (M)
Fig. 26 Trace showing the effect of DALDA (10"7M) before and 
after rapid pacing in the same heart.
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Fig. 27 Effects of (A) DALDA and (B) DAMGO on force of contraction 
in "unstressed” hearts and hearts subjected to "stress" by rapid pacing 
or ischemia. *P < 0.05 for hearts vs control **P < 0.005 for each control 
vs untreated hearts.
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4.7 DISCUSSION
The present study demonstrates highly selective p-opioid agonists can significantly alter the force of 
contraction of the heart. The inotropic effects of the p-agonists employed in this study can occur in 
either direction depending on the pre-existing condition of the heart. DAMGO and DALDA caused 
a negative inotropic response in the "unstressed" heart accompanied by significant negative 
chronotropic effects and a reduction in coronary flow. When the chronotropic effects were eliminated 
by electrical pacing of the heart at spontaneous rate, a much larger negative inotropic effect was 
unmasked. In contrast, hearts stressed by ischemia or rapid pacing responded to DAMGO and 
DALDA with positive inotropic effects that were also accompanied by a reduction in heart rate and 
coronary flow. The p-opioid agonists used in the present study were found to be highly potent, 
working at doses far below those previously reported for other opioid-agonists. -
The normal contraction of the heart is caused by a large Ca release from the main intracellular Ca 
store, the sarcoplasmic reticulum (Bers, 1985). This results in a rise in the cytoplasmic Ca 
concentration known as the "C% transient". The rise in the Ca, transient activates the myofilaments 
to slide resulting in an increase in the force of contraction of each cardiac muscle cell. When this is 
scaled up to the level of the whole heart, the increased contraction of each individual cell is translated
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into a greater strength of contraction of the whole ventricle. Ca release from the sarcoplasmic 
reticulum (SR) is triggered by a small Ca entry into the cell that occurs during the normal cardiac 
action potential. This Ca entry in turn triggers a much larger SR Ca release via the mechanism of "Ca- 
induced-Ca release"(Fabiato, 1983; 1985a,b,c) summing up the excitation-contraction process. There 
are a number of sites in the excitation-contraction coupling process at which drugs may exert 
inotropic action. Modulation of the excitation-contraction process can occur in one of four ways: 
modulation of the trigger stimulus which cause Ca release from the SR, alteration of sensitivity of the 
SR release mechanism for a given trigger stimulus, alteration of the releasable Ca content of the SR 
and finally myofilament sensitivity may be modulated to cause an increased or decreased 
responsiveness to Ca.
Several studies in cardiac cells have documented the point at which opioid agonists modulate the 
excitation-contraction coupling process to produce inotropic effects. The negative inotropic effects 
of U50,488H as well as Leu- and met-enkephalin were correlated with a decrease in Ca* transient 
(Ventura et al, 1992). Morphine was also shown to increase both the calcium influx and C% transient 
in rat myocytes (Ela etal, 1993). In another study, dynorphin and U50,488H were found to increase 
Caj transient by mobilizing calcium from an intracellular pool most likely the SR (Tai et al, 1992). 
Ventura and co-workers (Ventura eta l, 1991) demonstrated that a short exposure of myocytes to 
U50,488H resulted in both an increase in Ca, transient and enhancement of the myofilament 
responsiveness that resulted in an increase in contractility while, longer exposures caused a depletion
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of SR calcium resulting in a decrease in Cai transient and negative inotropic effects. A study on the 
effects of leu-enkephalin on the Ca2+ current (/Ca) of L-type Ca2+ channels concluded the negative 
inotropic effects of the opioid peptide are due in part to a reduction in / Ca. In addition, opioid peptides 
have been shown to inhibit Na+ - K+ and Ca2+ - dependent ATPase activities in bovine cardiac 
sarcolemma (Ventura etal, 1987). As Ca2+ entry into the myocardial cell is thought to be regulated 
by Ca2+ - dependent ATPase (Dhalla et al, 1982), this may explain, the Jno4ropic .a'.t effects of 
opioids. It is noteworthy that previous studies on the effect of opioids on contractile amplitude and 
mechanisms have employed much higher drug doses than those used in the present study. In addition, 
while there are numerous studies on the contractile effects of opioid receptor agonists on cardiac cells, 
relatively few studies have been done on the inotropic effects of selective opioid agonists in the whole 
heart isolated from systemic influences.
In ischemia and experimental heart failure induced by rapid pacing the homeostasis of the heart is 
altered (For review, see (Zucchi and Ronca-Testoni, 1997). Contractility of cardiac muscle cells is 
impaired as confirmed in the present study. Other alterations in the heart include a change in the Cai 
transient, SR Ca2+ channel receptor and Ca2+ uptake (Zucchi and Ronca-Testoni, 1997). Therefore 
a drug with inotropic effects administered under the different contractile states of the "stressed" 
versus "unstressed" heart may have altered effects as observed in the present study. However, the 
mechanism of action responsible for the difference in the inotropic effects ofDAMGO and DALDA 
under these conditions of the heart is unclear at the present time. From the present study, it appears
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the controversy surrounding the different direction of inotropic effects observed with opioids in 
previous studies is probably due to a lack of consistency in the investigative methods employed 
leading to different contractile conditions of cardiac systems. A study comparing inotropic actions 
of U50,488H between normal and cardiomyopathic ventricular cells showed no difference in the 
contractile response to U50,488H in the two groups (Kasper et al, 1992) indicating this phenomenon 
might be receptor-specific.
Glycosides and other traditional positive inotropic drugs such as P-adrenoceptor agonists and 
phosphodiesterase inhibitors used for the treatment of congestive heart failure (CHF), improve 
cardiac contractility by enhancing intracellular calcium (Packer, 1988; Levi et al., 1994). Their 
mechanisms of action include receptor-mediated stimulation of the adenylate cyclase-cAMP second 
messenger system, inhibition of K+, Na+-ATPase and inhibition of cAMP breakdown. Inhibition of 
the K+, Na+-ATPase will elevate intracellular Na+ leading to an increase in calcium influx through the 
Na7 Ca2+ exchanger, a phenomenon which has been reported to also occur in response to opioid 
peptides in isolated sarcolemma from ovine hearts (Ventura et al, 1987). The effects ofDAMGO 
and DALDA in the pathologic heart may also be indicative of a change in the underlying Ca^  transient 
which will in turn produce a secondary effect on Na and Ca fluxes via the Na+/ Ca2+ exhanger so that 
the altered response is a reflection of the different starting conditions of a lower Na^  and smaller 
contraction. It is interesting to note that our pilot studies showed that in addition to the positive 
inotropic effects observed with DAMGO and DALDA, they also eliminated the arrhythmias resulting
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from impaired coronary perfusion. This is similar to the action of Digitalis glycosides which are both 
positively inotropic in the failing heart as well as anti-arrhythmic via a depression of atrioventricular 
node conduction (for review, see Levi et al, 1994).
Contractility of the heart is pH-sensitive therefore the mechanisms that regulate intracellular pH are 
important in controlling cardiac contractility. A number of studies have shown that intracellular 
acidosis during ischemia increases sarcolemmal Na+/ H+ exchange during reperfiision (Deitmer and 
Ellis, 1980; Ellis and MacLeod, 1985; Kaila and Vaughan-Jones, 1987). The sarcolemmal Na-H 
exchange regulates pH by extruding H ions and taking up Na ions. This decreases the myofilament 
responsiveness to calcium in addition to a possible depletion of the SR Ca2+ pool (Atar et al, 1995; 
G&o et al, 1995; Ela etal, 1993) . Hence acidosis results in negative inotropy (Fabiato and Fabiato, 
1978), whereas alkalosis produces a positive effect. Opioids have been shown to produce both 
intracellular acidosis (Ela etal, 1993) and alkalosis (Kiang and Colden-Stanfield, 1990; Isom et al, 
1987). However, a study on the activation of NaV H+ exchange revealed acidosis-induced activation 
of the Na+/ H+ exchanger can result in different contractile effects depending on extracellular pH 
(Vaughan-Jones et al, 1989). Hence, if intracellular acidosis is accompanied by a reduction in 
extracellular pH, a negative inotropic response will occur while the same fall in intracellular pH at 
normal extracellular pH results in an increase in contractility. This difference in contractile response 
was found to be due to an acidosis-induced elevation of intracellular Na at normal extracellular pH 
resulting in aninerease in Ca influx via the Na-Ca exchanger. Hence, it is feasible that the difference
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in the contractile response ofDAMGO and DALDA in the "stressed" versus "unstressed" hearts is 
a reflection of a difference in extracellular pH under the two conditions.
A newer experimental approach in the treatment of CHF is the development of calcium-sensitizing 
drugs such as sulmazole and levosimendan which directly improve myocardial contractile force by 
increasing the affinity of the regulatory site of contractile proteins for calcium rather than enhancing 
intracellular calcium concentrations (for review, see Vegh et al, 1995). Calcium sensitizers improve 
myocardial contractility by stabilizing the calcium-induced conformational changes in the contractile 
component of the myofilament troponin-C (Vegh et al, 1995). It is possible that the difference in the 
inotropic actions ofDAMGO and DALDA in the normal versus stressed heart is due to different 
conformational changes in troponin-C in the normal versus stressed heart resulting in a decreased 
sensitization to calcium in the normal heart and increased sensitization in the stressed heart. This 
however, remains to be investigated.
In conclusion, this study confirms the differences in the contractile state of the normal heart and hearts 
subjected to stress. These differences result in an altered response of the inotropic effects of p- 
opioid peptides on the heart. Biochemical studies on the effect of opioid peptides on 
phosphodiesterase activity, intracellular cyclic A M P  level, C a2+  binding to sarcolemma and C a 2 +  
uptake by the SR and of possible effects on the contractile apparatus to mention a few are required 
to clarify the mechanisms by which p-opioid receptor peptides exert inotropic effects on the heart.
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CHAPTER 5
THE DEVELOPMENT OF RAPID TOLERANCE TO THE 
CARDIOVASCULAR EFFECTS OF p-OPIOID AGONISTS IN
VIVO AND IN VITRO.
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5.1 ABSTRACT
As previously reported, the highly selective p-opioid receptor agonists DAMGO ([D-Ala2, 7V-Me- 
Phe4,Gly5-ol]enkephalin) and DALDA (Tyr-D-Arg-Phe-Lys) have profound cardiovascular effects 
in the chronically instrumented ewe. In the present study, the effect of repeated exposure to these 
agonists and the possible development of tolerance to their cardiovascular effects is investigated. In 
the chronically-instrumented ewe, single exposures to DAMGO (0.3mg/kg) or DALDA (0.6mg/kg) 
resulted in a sign ificant increase in blood pressure with DAMGO eliciting a significantly larger 
response than D AT D A When two doses of the same agonist were administered 30 min apart, the 
pressor responses to the second doses of both DALDA and DAMGO was completely abolished. The 
possibility of cross tolerance between the two p-agonists was also investigated. Pretreatment with 
DAMGO completely abolished the pressor effect to DALDA. In contrast, pretreatment with DALDA 
resulted in a partial though significant attenuation of the pressor response to DAMGO. Hence the 
efficacy of DAMGO and DALDA in eliciting cardiovascular responses paralleled their ability to 
induce tolerance . In the isolated guinea pig heart, increasing doses of DALDA (10'n - 10'7M) 
separated by a 10 min drug washout between doses resulted in a dose dependent decrease in the force 
of contraction. However, when the heart was continuously exposed to the same drug treatment for 
30 min without allowing for washouts between doses, the inotropic effect of DALDA was completely 
abolished after 10 min. This study demonstrates acute tolerance to the cardiovascular effects of highly 
selective p-opioid agonists in vivo and in vitro.
117
5.2 INTRODUCTION
While opioid agonists are the drugs of choice in the management of severe and chronic pain, a 
prominent characteristic of their action is their ability to induce tolerance and dependence thus limiting 
their therapeutic efficacy. The p-opioid receptor is of critical importance in the development of 
tolerance and addiction (Loh et al., 1988; Di Chiara and North, 1992) and previous studies have 
reported the development of tolerance to the effects of morphine on heart rate and respiratory rate 
following a single dose exposure in rabbits (Hovav and Weinstock, 1987). More recently, it has been 
appreciated that tolerance can develop to opioid drugs even after brief exposure. Tolerance to the 
analgesic effect of alfentanil and remifentanil develops during constant rate infusion of these drugs in 
rats and humans (Kissing a/., 1996; Vinik and Kissin, 1998) and this rapid development of tolerance 
has been termed acute or short-term tolerance. The experimental conditions known to influence the 
development of acute tolerance to opioid drugs include dose, magnitude of effect, duration of drug 
action, and the time interval between doses (Hovav and Weinstock, 1987).
In the studies reported previously, the profound cardiovascular effects of the highly selective p-opioid 
receptor agonists DAMGO and DALDA have been demonstrated in vivo (Omoniyi et aL, 1998b, 
Clapp et al, 1996; Clapp et al, 1998). In the present study, the possibility of tolerance to the 
cardiovascular effects ofDAMGO and DALDA are investigated in vivo and in vitro.
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5.3 MATERIALS AND METHOD
5.3.1 In vivo studies (chronically instrumented sheep)
Following a 2 hour control period, each animal received one of the four drug treatments given in
Table 4. The second dose was administered 30 min after the first dose. Each animal was allowed a
on -tucd <Acy
minimum of 2 days between drug treatments and only received each drug treatment once. The order 
of drug treatment was randomized.
5.3.2 In vitro studies (isolated guinea pig hearts)
Following the stabilization period, hearts were perfused with DALDA in increasing doses of 10 , 
10"9 and 10"7M. Each dose was administered for 10 min followed by a 10 min recovery period during 
which the heart was perfused with drug free Krebs-Henseleit buffer. To investigate the possibility of 
tolerance to DALDA, all three doses were administered consecutively without the 10 min washout 
between doses. Only one dose response study was carried out per heart.
5.4 Data analysis
Blood pressure was analyzed using 1 min intervals and control values were averaged over 5 min prior 
to the administration ofDAMGO or DALDA. Mean arterial pressure was calculated as the diastolic 
pressure plus 1/3 of the pulse pressure. Force of contraction of the isolated heart was analyzed using 
two min intervals. Control values were averaged over 5 min prior to the administration of DALDA.
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5.5 Statistical analysis
All data are reported as mean ± S.E.M. One-way analysis of variance (ANOVA) with repeated 
measure (factor = time) was used to examine the effects ofDAMGO or DALDA on blood pressure. 
In cases where test of normality failed, ANOVA by ranks was used. Dunnett's test was used for post- 
hoc comparison of each time point to the pre-drug control. The differences between first and second 
drug administrations were evaluated using Friedman's two-way ANOVA with repeated measure 
(factors = treatment, time). Differences were considered significant whenP <0.05.
TABLE 4:Methods for in vivo drug treatment
Drug treatment First drug Second drug n
I DAMGO DAMGO 3
n DAMGO DALDA 3
m DALDA DALDA 3
IV DALDA DAMGO 3
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5.6 RESULTS
5.6.1 In vivo experiments
The first dose ofDAMGO (0.3 mg/kg) resulted in a significant increase in blood pressure (P < 0.001), 
and post-hoc comparison showed blood pressure was significantly elevated up to 8 min after drug 
administration (Fig. 28, top panel). When a second dose ofDAMGO was administered 30 min after 
the dose of DAMGO, there was no change in blood pressure (Fig. 28, top panel). However, a 
significant pressor response was observed when DAMGO was administered 30 min after DALDA, 
although the response was significantly attenuated when compared to a single dose ofDAMGO alone 
(P< 0.002).
The first dose of DALDA (0.3 mg/kg) also significantly increased mean blood pressure (P < 0.001), 
but the increase was smaller in magnitude and was only significant for 4 min after administration (Fig. 
29, top panel). Administration of DALDA 30 min after either DALDA or DAMGO produced no 
effect on blood pressure (Fig. 29, top panel).
DAMGO had no effect on heart rate when administered singly or following pretreatment with itself 
or DALDA (Fig. 28, bottom panel). In contrast, while a single exposure to DALDA had no effect 
on heart rate, a significant bradycardia (P < 0.05) was observed when DALDA was administered 30 
min after DAMGO (Fig. 29, bottom panel).
In contrast to DAMGO and DALDA, a repeat dose of U50,488H (0.6mg/kg) produced the same 
pressor effect and increase in heart rate as that observed with the first dose (data not shown).
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5.6.2 In vitro experiments
Perfusion of the heart with DALDA (10"n - 10*7M) separated by a 10 min washout resulted in a dose- 
dependent decrease in force of contraction (Fig. 30, top panel), heart rate (middle panel) and coronary 
flow (bottom panel). The decrease in force of contraction was highly significant (P < 0.02) and post- 
hoc comparison revealed that force of contraction was significantly decreased with all three drug 
concentrations. In contrast, the same doses of DALDA administered consecutively without allowing 
for drug washout between doses resulted in a loss of the negative inotropic response following the 
first dose. There was a significant difference between the two inotropic dose-response curves (P < 
0.001). There was no significant difference in the heart rate and coronary flow responses(fig. 30).
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Fig. 28 Effects of i.v. DAMGO (0.3mg/kg) on mean blood pressure 
(top panel) and heart rate (bottom panel) in untreated animals, 
animals pretreated with DAMGO and animals pretreated with 
DALDA (n = 3). Data are presented as means + S.E.
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Fig. 29 Effects of i.v. DALDA (0.6mg/kg) on mean blood pressure 
(top panel) and heart rate (bottom panel) in untreated animals, 
animals pretreated with DALDA and animals pretreated with 
DAMGO (n = 3). Data are presented as means + S.E.
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Fig. 30 Effects of DALDA (10"n-10"7M) on force of contraction (top panel), 
heart rate (middle panel) and coronary flow (bottom panel) when administered 
intermittently and continuously in the guinea pig heart (n = 6). Data are 
presented as : meansTS.E. o intermittent
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5.8 DISCUSSION
The present study demonstrates rapid tolerance to the cardiovascular effects of selective p-opioid 
agonists in vivo and in vitro. As reported previously, both DAMGO and DALDA caused a significant 
increase in blood pressure with no effect on heart rate when administered to the unanesthetized ewe 
(Clapp et al, 1996; Clapp et al, 1998). DAMGO was found to be more potent than DALDA when 
administered intravenously, and this is in accordance with the relative potency of these two p-opioid 
agonists in the guinea pig ileum (Schiller et al, 1989). The lack of a bradycardia in the presence of 
a pressor response was shown to be due to blunting of the baroreflex (Omoniyi et al, 1998a; Omoniyi 
etal, 1998b). Tolerance to the pressor effect ofDAMGO and DALDA was observed after exposure 
to a single dose of the drug, with the second dose producing no measurable effect on blood pressure. 
The dose interval used in this study (30 min) was much less than the shortest interval that was thought 
to be necessary for the development of acute tolerance to morphine (4 h) (Hovav and Weinstock, 
1987). Furthermore, administration of one p-agonist resulted in cross-tolerance to the other, with 
the more potent DAMGO producing complete tolerance to DALDA but DALDA resulting only in 
partial tolerance to the pressor effect ofDAMGO. In the isolated perfused heart studies, the rapid 
development of tolerance made it impossible to obtain a dose-response curve for DALDA using an 
escalating dose design. However, when a 10 min washout period was allowed between doses, a dose- 
dependent decrease in force of contraction became apparent.
The attenuation of responses to an agonist can occur at the level of the agonist, the receptor, the G-
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proteins, and at numerous steps downstream of the signaling pathway. Mechanisms for the attenuated 
response to repeated agonist response include receptor desensitization, receptor endocytosis 
(internalization), receptor phosphorylation and receptor downregulation (for review, see Grady et aL, 
1997). All four mechanisms have been implicated in the reduced responsiveness to repeated or 
continuous exposure to opioid agonists. Thus, internalization of the p-receptor following agonist 
exposure has been reported in human embryonic kidney (HEK) cells (Burford NT et ah, 1998) and 
neurons in vivo (Stemini et aL, 1996). The p-receptor was also shown to be due to internalization 
via clathrin-coated vesicles (Kato et aL, 1998). The desensitization observed with DAMGO in one 
study was correlated with a down regulation of p-receptors (Pak et aL, 1996), while numerous other 
studies have shown that repeated exposure to opioid agonists results in receptor phosphorylation.
The mechanism involved in the attenuation of agonist response is dependent on the length of exposure 
to the stimulus. Receptor desensitization occurs during short term exposure to agonists and is 
mediated by uncoupling of activated receptors from G proteins. With continuous exposure, the 
receptor becomes sequestered depleting the plasma membrane of high affinity receptors. When the 
stimulation is chronically persistent, this results in downregulation of receptors and hence a reduction 
in receptor density. Desensitization appears to develop very rapidly for both p and ô opioid receptor, 
within 3 min of exposure to opioid agonists (Zhang et aL, 1996; Pei et aL, 1995). It is therefore not 
surprising that tolerance to the negative inotropic action of DALDA was apparent within 10 min of 
perfusion in the isolated perfused heart system, and complete tolerance to the pressor effect of
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DAMGO and DALDA was observed 30 min after drug exposure. It is also interesting that it was 
possible to overcome the development of tolerance in the isolated heart by a 10 min washout period, 
just as it was reported that ô opioid receptors in NG108 cells can be re-sensitized with a time constant 
of 6.7 min (Morikawa et al, 1998).
G-protein cascades activated by p receptors can also reduce adenylyl cyclase activity, alter inositol 
triphosphate turnover, activate G-protein linked, inwardly rectifying potassium channels and mitogen- 
activated protein kinase, and close calcium channels (Childers, 1991; Loh and Smith, 1990). 
Attenuated responses to several of these effectors have also been demonstrated for repeated opioid 
agonist exposure in cells containing stably transfected opioid receptors. In agreement with the present 
study, desensitization was observed with DAMGO-induced potassium channel responses in Xenopus 
oocyte (Zhang etal, 1996), G protein activation in NG108-15 cells (Fan GH et al, 1998) and HEK 
cells (Burford NT et al, 1998), and forskolin-stimulated cAMP accumulation in CHO cells (Pak et 
al, 1996).
Another mechanism suggested for desensitization of the p-opioid receptor is receptor 
phosphorylation. Increased phosphorylation of the p-opioid receptor protein was demonstrated after 
as little as 5 min of exposure to DAMGO \n Xenopus (Zhang et al, 1996). The rank order for various 
opioid agonists in desensitization generally paralleled the rank order for phosphorylation of the p- 
opioid receptor in CHO cells (Yu et al, 1997). Receptor phosphorylation has also been shown to
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be coupled to desensitization of the ô-opioid receptor (Pei et al, 1995; Hasbi et al, 1998). Several 
studies have suggested the involvement of protein kinases in opioid receptor desensitization. 
Activation ofPKC was found to reduce the responsiveness of p-opioid receptors in Xenopus oocytes 
(Chen and Yu, 1994) and another study demonstrated the involvement ofPKC in the functional 
uncoupling of ô-opioid receptors from G-proteins (Fukushima et al, 1994). The overexpression and 
inhibition of PARK1 has also been shown to enhance and inhibit opioid receptor desensitization 
respectively (Raynor et al, 1994b; Pei et al, 1995).
The present data suggest that DAMGO is also more potent in producing tolerance than DALDA since 
pretreatment with DALDA was only able to partially attenuate the pressor response to DAMGO. 
Few cellular experiments have examined the phenomenon of desensitization with different opioid 
agonists. There appears to be a correlation between the efficacies of these opioid agonists in 
increasing blood pressure and their efficacies in inducing desensitization, and is in agreement with 
previous studies that show a correlation between agonist efficacy and level of desensitization 
(Yabaluri and Medzihradsky, 1997; Yu et al, 1997).
In conclusion, this study demonstrates a rapid tolerance to highly selective p-opioid agonists in vivo 
and in vitro. The specific mechanism by which these p-opioid agonists cause receptor desensitization 
in these systems remains to be investigated.
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CHAPTER 6
A GENERAL DISCUSSION
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6.1 Discussion
In the intact and unanesthetized animal, the p-opioid agonists DAMGO and DALDA, as well as the 
K-agonist, U50,488H had significant effects on blood pressure. These results contradicted that of 
several other studies involving the use of anesthesia confirming earlier reports on the ability of 
anesthetics to reverse the cardiovascular effects of opioids. The pressor effects of all three agonists 
was sensitive to naloxone. Furthermore, the pressor effects of DAMGO and DALDA was also 
sensitive to the quaternary opioid antagonist naloxone methiodide, in contrast to the generally held 
belief that these agonists affect blood pressure via a central site.
The investigation into the cardiovascular effects of these p-agonists was then focused on an in vitro 
of
setup with the aim^elucidating the mechanism involved in their profound pressor effects. The initial 
expectation had been that DAMGO and DALDA would increase myocardial contractility thus 
explaining the pressor responses observed in vivo. This hypothesis was based on preliminary data 
from James F. Clapp'^laboratory which indicated that these agonists increased cardiac output in the 
ewe while having no effect on peripheral resistance. Considering the lack of any effect on peripheral 
resistance, it was thought that the increase in cardiac output hence blood pressure was due to a direct 
action of p-agonists on the heart to increase contractility and/or venous return. In light of the isolated 
heart results, the increase in blood pressure is most likely due to an increase in venous return. In fact, 
preliminary data now confirms that DALDA significantly increases venous return in the 
unanesthetized ewe (unpublished data from collaborator). This is in agreement with a study in the
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conscious rat which demonstrated a concomitant increase in blood pressure and cardiac output with 
no accompanying change in total peripheral resistance (Siren and Feuerstein, 1991).
The isolated heart study however still demonstrated highly selective p-opioid agonists can significantly 
alter the force of contraction of the heart. Whatimore, these p-opioid agonists were found to be 
highly potent, working at doses far below those previously reported for other opioid-agonists. It is 
also interesting that the effect of DAMGO and DALDA on myocardial contractility can occur in either 
direction depending on the pre-existing condition of the heart and that its chronotropic effects can 
significantly masks/ its inotropic response. Both the negative and positive inotropic actions of 
DAMGO and DALDA were attenuated by the non-selective opioid antagonist naloxone indicating 
the guinea pig heart may contain p-opioid receptors in contrast to that reported for the rat (Krumins 
et al, 1985). Alternatively, it ispossible that the effects of p-opioid agonists is not as a result of a 
direct effect on the myocardium. Instead the cardiodepressant effects of DAMGO and DALDA on 
the heart may be due to actions on sympathetic and/or parasympathetic nerve terminals. This would 
be consistent with reports which demonstrate the presence of opioid receptors in the vagus nerve 
(Young et al, 1980; Zarbin et al, 1990) and sympathetic nerve terminals in the heart and blood 
vessels (Mantelli et al, 1987). The mechanism behind the unusual difference in the inotropic response 
of the "stressed" versus "unstressed" heart is not understood at the present time and warrants fiirther 
investigation. It is almost certain that it could be explained by the effects of these p-agonists on 
calcium fluxes in the heart. The use of cardiac myocytes would be ideal in the mechanistic
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evaluation of the effects of DAMGO and DALDA on the force of contraction of the heart.
The negative chronotropic effects of p-opioid agonists observed in vitro were in sharp contrast to the 
lack of a bradycardia seen in vivo. It is posiible that in vivo, the lack of a bradycardia may be partially / / z  
due to an underlying increase in sympathetic activity in response to DAMGO and DALDA. 
Furthermore the differences in the cardiovascular state of in vivo and in vitro setups i.e. the absence 
of autonomic tone, baroreflexes etc may account for the differences observed between the effects of 
p-opioid agonists in vivo and in vitro.
These studies also demonstrated a significant attenuation of the cardiovascular effects of opioid 
agonists in pregnancy. As previously explained, significant vascular changes occur in pregnancy.
These profound changes in the physiology of the pregnant animal may account for differences in its 
response to vasoactive drugs. Many of these changes are thought to be mediated by estrogen 
receptors located throughout the vascular tree. However, progesterone probably also plays a role as 
progesterone receptors are also present throughout the vascular tree and have been shown to modify 
responses to estrogen. Thus, it is logical to assume that many of the altered responses to vasoactive 
drugs during pregnancy are the result of an altered hormonal milieu, however this has not been 
confirmed in either an animal or human model.
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^-agonists had no effect on heart rate while the k -  agonist, U50,488H caused a significant 
tachycardia. The results of the baroreflex study demonstrate for the first time that systemically- 
administered g-opioid peptide analogs can significantly alter baroreflex sensitivity in both nonpregnant 
and pregnant animals. Interestingly, both DAMGO and DALDA blunted the baroreflex-mediated 
bradycardia to pressor stimuli, but had no effect on the baroreflex-mediated tachycardia to a 
hypotensive stimulus. These results also suggest that, in addition to opioid receptors in the CNS, 
peripheral opioid receptors may also play an important role in inhibiting the baroreflex. In contrast 
to p-agonists, the k -  agonist, U50,488H had no effect on the baroreflex and its tachycardie effect 
was found to be mediated by sympathetic activation of the heart. This indicated that unlike p- 
agonists, systemically administered K-agonists appear to possess a central component to their 
cardiovascular effects.
The attenuation of baroreflex-mediated bradycardia observed with p-agonists could be as a result of 
inhibition of vagal activity by DAMGO and DALDA. Other opioid receptor agonists such as 
morphine and the enkephalins have been shown to inhibit the bradycardia elicited in response to vagal 
stimulation (Musha et al, 1989; Weitzell et al, 1984). In addition, enkephalins were also found to 
inhibit the release of acetylcholine from rabbit atria (Weitzell et al., 1985; Wong-Dusting et al., 1985).
To further support this hypothesis are previous studies documenting the presence of opioid receptors 
on the vagus (Young et al, 1980; Zarbin et al, 1990). Blunting of the bradycardic response to 
pressor stimuli may also be due to a direct inhibition of the baroreceptors, or modulation of the
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afferent or efferent pathways to and from the NTS. However, data from these study showed that the 
baroreflex-mediated tachycardia to hypotensive stimuli was not affected, suggesting that p-agonists 
must be inhibiting vagal efferents to the sino-atrial node, p-agonists may inhibit vagal activity either 
prejuktionally by reducing acetylcholine release or postjuntionally by interfering with the action of 
acetylcholine at its receptors. It would be expected that an inhibition of the bradycardic response 
to vagal nerve stimulation by these p-opioid agonists would be significantly blunted in pregnant 
animals. Finally, if DAMGO and DALDA shift the dose-response to exogenously administered 
acetylcholine, pregnant and hormonally-treated hearts will show less of a rightward shift. Likewise, 
since_p-opioid agonists exert a direct effect on the myocardial contractility in the nonpregnant guinea 
pig heart, it is likely that the dose-response relationship in hearts from pregnant animals will be shifted 
to the right. These differences may be associated with a reduction of p-receptors in the heart or vagal 
terminals of the pregnant animal, or a change in binding affinity. These findings could then be 
confirmed by opioid receptor binding assays in the vagus and cardiac tissues.
The rapid development of tolerance to the cardiovascular effects of DAMGO and DALDA found 
in vivo and in vitro may also be limited to p-agonists as preliminary data with U50,488H and another 
K-opioid agonist orphanin indicates that k- unlike p-opioid agonists do not induce tolerance following 
repeated systemic administration. The specific mechanism by which DAMGO and DALDA induce 
tolerance also remains to be investigated. While desensitization at the level of the receptor seems the 
most likely cause of the attenuation to the cardiovascular effects of DAMGO and DALDA, other
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causes of tolerance cannot be ruled out. These include receptor endocytosis (internalization), 
receptor phosphorylation and receptor downregulation. All four mechanisms have been implicated 
in the reduced responsiveness to repeated or continuous exposure to opioid agonists (Burford NT 
et al, 1998; Stemini et al., 1996; Kato et al, 1998; Pak et al, 1996).
6.2 Conclusion
In conclusion, these studies together demonstrate p- and K-opioid agonists have significant 
cardiovascular actions in the intact animal and directly at the level of the heart. While both p- and 
K-opioid agonists have similar effects on blood pressure, the heart rate response to K-opioid agonists 
differ significantly from those of p-agonists in site and mechanism of action. These studies also 
demonstrate for the first time that the highly selective p-opioid agonists DAMGO and DALDA blunt 
baroreflex-mediated bradycardia but not tachycardia following systemic administration. The effects 
o f p-agonists on the baroreflex like its pressor effects also occur at a peripheral site. The 
cardiovascular effects of both p- and K-opioid agonists were significantly attenuated in pregnancy. 
For the first time, the inotropic and chronotropic effects of p-agonists on the heart are shown to be 
subject to the state of the myocardium. Furthermore, repeated or continuous exposure to these 
agonists results in the rapid development of tolerance to the cardiovascular effects observed in vivo 
and in vitro. Finally, the two p- agonists DAMGO and DALDA though producing similar effects 
in all studies carried out, displayed different levels of potency. DAMGO blunted the baroreflex to a 
higher degree, produced bigger chronotropic and inotropic effects in the isolated heart and induced
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a higher level of tolerance than DALDA in accordance with the relative potency of these two p-opioid 
agonists in the guinea pig ileum (Schiller et al, 1989).
These studies demonstrate that highly selective p and K-opioid agonists in the absence of the 
confounding effects of anesthesia, produce profound cardiovascular effects. In contrast, 5-opioid 
agonists do not appear to have any effects on either blood pressure or heart rate. These studies clearly 
resolve the confusion regarding the direction of change of blood pressure, heart rate and baroreflex 
sensitivity in response to opioid agonists. The direct actions of DALDA and DAMGO on the force 
of contraction of the heart, isolated from systemic influences is also demonstrated for the first time. 
It is particularly interesting that these opioid agonists have a different and possibly protective effect 
in the stressed heart indicating a possible therapeutic role for opioid agonists in the compromised 
heart.
y
The pressor, heart rate and baroreflex effects of these opioid agonists are also demonstrated in 
pregnancy and shown to be altered when compared to nonpregnant animals. More importantly, the 
present study demonstrates there are no serious cardiovascular side effects produced in the mother 
when exposed to these opioid agonists increasing their potential for clinical use. However, like its 
counterparts, there is a development of rapid tolerance following exposure to the (i-opioid agonists 
DAMGO and DALDA.
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